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Roman Goz, PhD 
University of Connecticut, 2018 
Abstract 
Low-grade neuroepithelial tumors (LNETs) are the most frequent tumors in patients 
undergoing resective surgery for epilepsy treatment. BRAFV600E represent the most frequent 
mutation in LNETs. In the RAS-RAF-ERK (MAPK) pathway activation of receptor tyrosine 
kinase leads to activation of BRAF protein. By mimicking constitutive activation of the kinase 
domain in RAS-independent manner BRAFV600E represents much higher activating substrate of 
MAPK pathway than BRAF wild type. Increased activation of MAPK leads to alterations of cell 
cycle progression, cell growth, proliferation, and cell fate. It also influences cortical neuron 
migration. Introducing human BRAFV600E into neuroglial progenitors in mouse cortex on 
embryonic day 14 to 15 induced astrogliosis. It also disrupted cellular morphology, causing 
appearance of balloon-like cells, disrupted neuronal migration to the upper cortical layers, altered 
tissue-wide gene expression, and induced neuronal hyperexcitability. Hyperexcitability was 
evident as higher action potential (AP) frequencies in response to depolarizing current injections 
in whole-cell current-clamp configuration of the patch-clamp technique; more depolarized by 7-
10 mV resting membrane potential (RMP) and increased by about 100 MΩ input resistance (Rin). 
Single APs showed more hyperpolarized voltage threshold in BRAFV600E expressing neurons 
and those neurons had lower minimal required current (rheobase) to fire APs. Increased initial 
deflection in response to the hyperpolarizing current pulses - SAG and a rebound excitation at the 
 




end of those pulses were observed, which was found to result from increase in the 
hyperpolarization activated conductance (Ih current). In whole-cell voltage-clamp configuration 
BRAFV600E neurons have increased Ih compared to the control conditions. Additionally, 
sustained, tetraethylammonium sensitive voltage activated potassium currents were decreased in 
BRAFV600E neurons. Activation of potassium currents with retigabine decreased action potential 
firing frequency. Recording of action potential dependent spontaneous post-synaptic currents 
(sPSCs) showed increased frequency in BRAFV600E neurons, those sPSCs frequencies were 
higher in untransfected neighbors. Video and Electrocorticographic recording in the freely moving 
mice showed spontaneous epileptiform activity with behavioral manifestations. The findings 
indicate that BRAFV600E mutations are sufficient to partially capture the pathophysiology of 
LNETs. The conclusion has implications to the possible courses of, and therapeutic targets for 
LNET associated epilepsy. 
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 Epilepsy affects about 50 million people worldwide.  Epilepsy patients with drug refractory 
recurrent seizures and disrupted brain structure on MRI are referred to resective surgery to 
remove epileptic foci (Blumcke et al., 2016). The second most common finding in epilepsy 
surgery patients, after focal cortical dysplasia (FCD) in children and young adults and after 
hippocampal sclerosis (HS) in adult patients are LNETs. LNETs are also the most frequent 
tumors found in resective surgery for epilepsy treatment patients. Ganglioglioma and DNETs 
represent the most frequent entities of this group. Together with malformations of cortical 
development (MCDs) like FCD, tuberous sclerosis (TSC) syndrome, and different types of brain 
growth disorders LNETs represent a group without known molecular mechanisms that cause 
ictogenesis and subsequent epileptogenesis (Barkovich et al., 2015; Crino, 2011). Disruption of 
cortical cytoarchitecture, cellular dysmorphogenesis and seizures that occur with different 
characteristic pathologic severity in all those disorders may share a common molecular pathway, 
overactivation of which may shift neuronal network together with astroglial components towards 
seizure prone states. Small groups of hyperexcitable neurons may be sufficient in such conditions 
to induce ictogenesis, and, permissive tissue environments may promote recurrent seizures, or 
epilepsy.  
 BRAFV600E mutations are the most frequent mutations in LNETs (Koelsche et al., 2013; 
Schindler et al., 2011). It is also one of the most studied mutations in solid cancers, and is found 
in papillary thyroid, colorectal and melanoma (Davies et al., 2002). I introduced human 
BRAFV600E by in-utero electroporation in a subset of cortical cells to develop a mouse model 
of LNETs. The results show a different histopathology, resembling pilocytic astrocytoma and 




ganglioglioma along with disruption in cortical cytoarchitecture, delayed neuronal migration, and 
increased astrogliosis.  
 In Chapter 1 I describe current definition of low-grade neuroepithelial tumors, their history 
and genetic etiology and relationship to specifically MCDs. I discuss the common molecular 
pathways shared between MCDs and LNETs. Further discussion is concentrated on BRAF 
protein and its’ function in the RTK-RAS-RAF-MEK-ERK pathway. Other pathways, mutations 
in which were found in LNETs are partially covered. Following subchapters I discuss possible 
hyperexcitability mechanisms and present findings from previous studies on different 
histopathological features and their presumed contributions to network hyperexcitability, 
glutamate ionotropic and metabotropic receptor alterations in MCDs and LNETs, and 
GABAergic receptor alterations. Microglial and astroglial mechanisms role in epileptogenesis in 
MCDs and LNETs are also discussed.  
 In Chapter 2 I present the research objectives and the methodological approach.  
 In Chapter 3 I present the results on alterations in cortical cytoarchitecture in BRAFV600E 
transfected animals versus control-Fluorophore (control-FP) transfected and BRAF wild type 
(BRAFwt). I show that expression of BRAFV600E has different effects on cells’ fate depending 
on the driver promoter used to label different neuroglial progenitor populations. Using 
Immunohistochemistry together with RNA-sequencing I show that BRAFV600E expression in 
mouse cortex activates astrocytes and induces expression of genes related to the inflammatory 
innate immune response, and genes including classic complement pathway. I show that 
BRAFV600E expressing neurons display hyperexcitability in whole-cell patch-clamp ex-vivo 
recording in coronal slices of somatosensory cortex. Expression of BRAF wild type did not 




cause hyperexcitability suggesting BRAFV600E mutation induces effects beyond overexpression 
of BRAF.  
 Alteration of ion channels may be a possible mechanism of hyperexcitability. In whole-cell 
current clamp BRAFV600E neurons reach action potential firing frequencies higher than all 
other conditions. BRAFV600E neurons also have more depolarized resting membrane potentials, 
require less depolarizing current to fire first action potentials, and display a more hyperpolarized 
voltage threshold. Additionally, BRAFV600E neurons have increased hyperpolarizing current 
induced voltage SAG, and elevated rebound excitation. These phenomena are a result of 
increased hyperpolarization activated depolarizing conductance, which was evident in whole-cell 
voltage clamp in BRAFV600E neurons.  
 More importantly BRAFV600E neurons have decreased sustained tetraethylammonium 
sensitive potassium currents. The hyperexcitability, exhibited as increased AP firing frequency 
was decreased in BRAFV600E neurons when retigabine, a Kv7.2-7.5, potassium channel 
activator was applied. Preincubation of cortical slices in BRAFV600E inhibitor, Vemurafenib 
(PLX4032, PLX4720) decreased the AP firing frequency, however the effect was 
indistinguishable from the effect of similar amount of its solvent – DMSO. Action potential 
dependent excitatory spontaneous post-synaptic currents frequencies, recorded at -70 mV 
holding potential, were increased in BRAFV600E neurons, but they also were increased even 
more in their untransfected neighbors, showing that there may be non-cell autonomous network 
effects. Unsupervised hierarchical cluster analysis showed segregation of BRAFV600E 
expressing neurons from other conditions based on 20 electrophysiological parameters recorded 
in ex-vivo whole-cell patch-clamp experiments. Finally, I make a comparison to other 




manipulations affecting neuroglial progenitors with MTOR regulatory component mutations, 
PIK3CA E545K and TSC1 loss of function using CRISPR-Cas9 system.  


















CHAPTER 1 INTRODUCTION 
Epilepsy is a spectrum disorder with more than 25 syndromes with varying types and severity 
of seizures. It is the fourth common neurological disorder affecting nearly 1 percent (~50 million 
people) of the population, decreasing the quality of life and increasing the risk of death. With 
approximately 2.8 million patients (5-8.4 of every 1,000 people) and 150,000 new cases (30-50 
out of 100,000) diagnosed each year in US only, with about 15.5 billion-dollar estimated economic 
burden. The incidence of newly diagnosed epilepsy cases in childhood and early adulthood is 
increasing. About 30% of epilepsy patients have seizures that are refractory to anti-epileptic drugs 
(AEDs). (Fisher et al., 2017; Scheffer et al., 2017; CDC, August 3, 2017; World Health Statistics 
2016: Monitoring health for the SDGs; Zack and Kobau, 2015; England et al., 2012; Russ et al., 
2012; World Health Organization, 2006).  
Epilepsy patients not responsive to at least two AEDs may be further referred for surgical 
resection of the affected brain area, excluding cases that involve eloquent or life sustaining brain 
centers (Blumcke et al., 2014; Alexandre et al., 2006). In 50-80% of the cases, depending on the 
extent of the affected area of resection, and the contribution of surrounding cortical tissue, surgical 
treatment is successful with no relapse over a two year follow up period (Wong, 2009; Alexandre 
et al., 2006). Amongst etiological causes the most frequent epilepsy resection surgery findings are 
malformations of cortical development (MCDs) and low-grade epilepsy associated neuroepithelial 
tumors (LNETs; previously – long-term epilepsy associate Tumors, LEATs) that involve varying 
degrees of cortical dyslamination and cellular dysmorphogenesis.  LNETs are the second leading 
cause of epilepsy after FCD in children and adolescents 0-19 years of ages and after HS in adults 
(Blumcke et al., 2016; Barkovich et al., 2015; Blumcke et al., 2014; Wong, 2013; Blumcke and 
Wiestler, 2002).  




1.1 LOW GRADE EPILEPSY ASSOCIATED 
NEUROEPITHELIAL TUMORS AND MCDS  
LNETs were first described in patients with a long history (>2 years) of intractable epilepsy. 
Due to their slow growth and frequent presence in epilepsy surgery patients, the initially introduced 
term was long-term epilepsy associated tumors (Luyken et al., 2003). With the new, less stringent 
clinical definition of epilepsy - MRI lesion findings with shorter history of seizures, and drug 
refractory epilepsy has been considered a sufficient criteria for epilepsy diagnosis (ILAE, 2017; 
Blumcke et al., 2016), The International League Against Epilepsy (ILAE) task force suggested 
changing  the definition to low-grade epilepsy associated neuroepithelial tumors (LNETs) 
(Blumcke et al., 2016). Cytoarchitectural changes in LNETs involve neuronal as well as glial 
components, with a predominant appearance in the temporal lobe  (Thom et al., 2012). The 
presence of similar cytological component in LNETs and FCDs, including balloon cells and 
hypertrophic dysmorphic neurons, and cortical dyslamination suggested a common developmental 
origin. Due to multiple cases of LNETs with FCD in the surrounding tissue the new ILAE FCD 
classification, FCD type IIIb is defined by association with tumors (Blumcke et al., 2011).  
Slowly growing LNETs are present in 25-80% of drug refractory epilepsy cases treated with 
resecting surgery (Pelliccia et al., 2017; Blumcke et al., 2016; Zanello et al., 2016; Barkovich et 
al., 2015; Guerrini et al., 2015; Nagarajan et al., 2015; Blumcke et al., 2014; Rossi, 2014; reviewed 
in Thom et al., 2012; Luyken et al., 2003; Blumcke and Wiestler, 2002; Schramm et al., 2001; 
Blumcke et al., 1999; Morris et al., 1998; Wyllie et al., 1998; Wolf and Wiestler, 1993; Silver et 
al., 1991; Rich et al., 1985; Spencer et al., 1984; Cavanagh, 1958). The major subtypes of LNETs 
- predominant in young patients ganglioglioma (GG) – about 5% of pediatric brain tumors 
(Blumcke et al., 2016; Barkovich et al., 2015), and dysembryoplastic neuroepithelial tumors 




(DNETs) in about 20-36% of cases are associated with FCD (Blumcke et al., 2014). FCD is 
considered a common cause for drug refractory epilepsy and is found in 25-46% of cases in both 
children and adults (Blumcke et al., 2014; Rossi, 2014; Wong, 2013; Bast et al., 2006; Cepeda et 
al., 2006; Cataltepe et al., 2005; Blumcke and Wiestler, 2002; Morris et al., 1998; Wyllie et al., 
1998). Although these statistics refer to the selected population of patients, which are surgically 
treated for epilepsy, FCDs and LNETs with varying severity may be present in epilepsy patients 
responsive to AEDs. In some cases, people diagnosed with FCD or LNETs may not develop 
epilepsy  (Maynard et al., 2017; Leach et al., 2014). One of the main questions raised by these 
studies is – how and whether multiple common components in different types of malformations 
induce seizures and subsequently epilepsy in some patients, and not in others? Knowledge of the 
minimum extent of the cortical malformation that is required for ictogenesis and epileptogenesis, 
and if there is an increase in a specific malformation component, dysmorphic neurons, for instance, 
that makes neuronal networks more seizures prone may help address these questions. Also, are 
there intrinsic neuronal properties that change in dysmorphic neurons and are they present in 
regular formed neighboring neurons, and what is the contribution of the glial component to 
seizures? Finally, does the somatic genetic alteration that shifts neuronal network to ictogenesis 
and subsequently to epileptogenesis in dysplastic cortex only involves malformed cells in a cell-
autonomous way, or does it involve non-malformed neurons and glia in a cell non-autonomous 
way? 
LNET co-occurrence with FCD (FCD IIIb) present an additional conundrum. Despite an 
extensive research on LNETs and FCDs and their relationship there is no consensus on whether 
the co-occurrence is a dual pathogenicity or whether there is a primary malformation that causes 
the secondary to occur. The source of the epileptogenesis in the co-occurrence cases is also not 




well understood (Palmini et al., 2013; Schwartzkroin and Wenzel, 2012; reviewed in Thom et al., 
2012; Kohling et al., 2006). To better understand the relation of LNETs and associated FCDs to 
epilepsy and its’ recurrence after the surgery there is a need to adopt a common/standardized 
methodological description of the extent of malformation (MRI, EEG, ECoG during the surgery), 
the extent of its’ resection, differential malformations susceptibility of the affected brain areas, and 
what dysregulated molecular mechanisms are involved in developmental tumorigenesis and 
surrounding cortical malformation (Blumcke et al., 2016; Schwartzkroin and Wenzel, 2012; 
Wong, 2009).  
Only recently has some consensus been reached on methods for classifying LNETs (Blumcke 
et al., 2016; Blumcke et al., 2014; Japp et al., 2013). Surgical resection of epileptogenic brain 
areas, the only available treatment for drug refractory epilepsy, is not suitable for a significant 
number of patients, either due to epileptogenic foci proximity to eloquent or life sustaining brain 
centers or simply unavailability of the procedure in many developing countries (World Health 
Organization, 2006). Importantly, following the surgical procedure seizures may relapse and 
tumors may recur (Blumcke et al., 2014; Thom et al., 2012; Wong, 2009). Hence there is a need 
to understand pathophysiological genetic and molecular mechanisms for elucidating the elements 
that increase probability of neuronal networks epileptogenesis. This may help to develop new 
treatments. This may be achieved through combined investigative methodologies and development 
of accurate animal models based on recent discoveries of recurrent somatic mutations in LNETs 








1.2 GENETIC ETIOLOGY 
Shared histopathological features between MCDs and LNETs led some to include one of the 
LNETs (GG) into the MCDs broad group of pathologies (Barkovich et al., 2015). The earliest 
documented cases date back around 200 years (Sims, 1835). Since then reports on more than 100 
genes associated with MCDs have been published. Alterations in genes that participate in cell-
cycle regulation, apoptosis, cell-fate specification, cytoskeletal structure and function, cell 
migration and post-migrational organization and growth have been implicated in MCDs and 
LNETs (ILAE, 2017; Parrini et al., 2016; Guerrini and Parrini, 2015; Barkovich et al., 2015; 2012).  
Genetic mutations in several molecular pathways involved in cortical development have been 
identified in known MCDs and LNETs (Barkovich et al., 2015; Lim and Crino, 2013; Zhang et 
al., 2013; Aronica et al., 2008a). Reduced cell proliferation found in microcephaly, or abnormal 
proliferation and possible neuro-glial differentiation of progenitors as in LNETs (Blumcke et al., 
2014), tuberous sclerosis complex (TSC) disorders (Crino, 2013), type II FCDs (Blumcke et al., 
2011); or abnormal cell migration, differentiation and growth as in megalencephaly (Roy et al., 
2015; Lee et al., 2012; Riviere et al., 2012) are pathogenic mechanisms that might cause both – 
MCDs and LNETs. However, it is still unclear whether epilepsy is a direct consequence of 
abnormal development of cortical cytoarchitecture, or whether the specific intrinsic cellular 
excitability mechanisms are changed, independent of malformation creating cells that are easily 
excited by synaptic inputs and/or spontaneously active to induce seizure prone networks. Some 
evidence that epileptogenicity is independent of brain malformation comes from recent PIK3CA 
mutated mouse models finding that epileptic foci are found outside the malformed cortex, and the 
identified by MRI FCD cases without epilepsy (Maynard et al., 2017; Roy et al., 2015; Kohling et 
al., 2006). However, the type of malformation in question, its severity (Palmini et al., 2013; Cepeda 




et al., 2006; Sisodiya, 2004; Frater et al., 2000), the population of progenitor cells involved within 
the boundaries of affected developmental stages (Way et al., 2009; Cepeda et al., 2006), genetic 
etiology, epigenetic modulation(Kobow and Blumcke, 2017; Becker et al., 2001) and 
environmental effects may all be contributing factors to epileptogenicity induction. Additionally, 
the “two-hit” hypothesis (Hino and Kobayashi, 2017; Stark and Otto, 2016; Knudson, 1996; 
Knudson, 1971; Nicholls, 1969) of Epilepsy suggests that there are second factors, for instance, 
pathological abnormalities of an autosomal dominant mutation (TSC) (Crino, 2013) (either 
germline or somatic) that must combine with – “environmental factors” to induce second somatic 
mutation (Feliciano et al., 2011; Wong, 2009; Takahashi et al., 2004; Wenzel et al., 2004). The 
possibility of multiple hits in cancer causation has been considered as well (Tomlinson et al., 
2001). Understanding the molecular, genetic and epigenetic factors contributing to or directly 
causing epilepsy may be possible with animal models.  
Ideal animal models of MCDs should capture key aspects of the abnormal cortical development 
– structural histopathology as well as electrophysiological cellular and network mechanisms, 
which increase propensity for epileptogenesis. The significant diversity in structural abnormalities 
found in different MCDs allowed development of multiple animal models capturing only partial 
characteristic pathologic findings while epileptogenesis been the main clinical manifestation of 
MCDs represented a relatively rare phenotype. In this case epileptogenic agents are used to 
demonstrate lower Ictogenic threshold, or, in-vitro electrophysiological and histochemical 
techniques used to characterize changes in cellular and network excitability (Schwartzkroin and 
Wenzel, 2012; Feliciano et al., 2011; Wong, 2009; Cepeda et al., 2006). Recently developed 
animal models demonstrate spontaneous ictogenesis and epileptogenesis, that might be 
independent of histopathological features of malformations, with genetic etiologies, present a 




promising platform for epilepsy treatment development (Baek et al., 2015; Nguyen et al., 2015; 
Roy et al., 2015; Lim et al., 2015; Ljungberg et al., 2009; Zeng et al., 2009). Consistent with the 
diverse histopathology in different MCDs and LNETs the cellular and network 
electrophysiological mechanisms that cause seizures in each MCD or LNET type and affected age 
group may be different (Cepeda et al., 2006).   
Some histopathological findings are shared in different conditions (Crino, 2013; Lee et al., 
2012). Balloon cells observed in FCD IIb resemble “giant” cells found in TSC disorder and 
ganglion cells found in GG. Dysmorphic mislocalized neurons were found in FCD II, TSC, GG, 
and DNETs. Disruption of cortical cytoarchitecture is present in those disorders with different 
levels of severity (Crino, 2013; Thom et al., 2012; Blumcke et al., 2011; Thom et al., 2011a). This 
led researchers to hypothesize that activation of common, major molecular pathways that regulate 
cellular proliferation, migration, differentiation and growth may result in seizures. One of the key 
pathways activated by growth factors, in which high frequency of mostly de-novo somatic mosaic 
mutations has been found in MCDs is the mechanistic target of rapamycin pathway 
(mTORC1,mTORC2 complexes, PI3KCA-AKT3-mTOR) (Blumcke and Sarnat, 2016; Hevner, 
2015; Crino, 2013; Lim and Crino, 2013; Wong, 2013). In respect to mutations found in MCDs 
(Crino, 2015), ligand binding to receptor tyrosine kinase leads to activation of phosphatidylinositol 
3-kinase catalytic alpha subunit (PI3KCA) that phosphorylates phosphatidylinositol-4,5-
biphosphate (PIP2) converting it to phosphatidylinositol-3,4,5-triphosphate (PIP3) (Gross and 
Bassell, 2014). That phosphorylation cause binding and activation AKT3 (Protein kinase B) (Choe 
et al., 2003). Another enzyme, phosphatase and tensin (PTEN) homolog converts PIP3 back to 
PIP2 reducing activation of AKT3 (Kreis et al., 2014). AKT3 phosphoinhibit TSC2 (tuberin) thus 
disrupting its binding with TSC1(hamartin) and causes activation of mTOR1 complex  (Inoki et 




al., 2002; Manning et al., 2002). AKT3 has more than 100 substrates and can affect cell growth 
and survival, by inhibiting the forkhead box O pathway (FOXO), and cell proliferation through 
inhibition of glycogen synthase kinase 3 (GSK3) pathway. The second pathway, extensively 
studied in melanoma and papillary thyroid cancers (Chen et al., 2012; McCubrey et al., 2012) and 
is hyperactivated in LNETs is RAS-RAF-ERK (MAPK) pathway. This pathway may be activated 
in parallel to mTOR pathway downstream of receptor tyrosine kinase (RTK – FGFRs, IGF1R, 
TRKB) (Blumcke et al., 2016; Hevner, 2015; Kumar et al., 2005). Those two pathways may 
interact (Pernice et al., 2016) through ERK1/2 phosphorylation of TSC2 and subsequent activation 
of mTORC1 (Ma et al., 2005). Additionally, BRAF may regulate  AKT3 through, possibly 
structural, kinase independent  interaction with rictor-mTORC2 complex (rapamycin insensitive 
component of mTOR) and prevention of mTORC2 enzymatic activity, or through raptor of 
mTORC1 complex protein (regulatory associated protein of mTOR) (Chen et al., 2012). Also RAS 
protein may directly participate in activation of mTOR pathway (Kumar et al., 2005) (Figure 1 - 
Molecular Pathways in MCDs and LNETs).  
 
Figure 1 - Molecular Pathways in MCDs and LNETs 
 
 
Figure 1. Activation of two molecular pathways implicated in cellular 
growth, proliferation, inhibition of autophagy and hyperexcitability. 
Activation of common to both pathways RTKs by extracellular signals 
leads to cellular alterations that may underlie multiple pathological 
conditions. Regulation of those pathways overactivation by inhibitors for 
specific components may be helpful in controlling those pathologies.  





PI3K-AKT3-MTOR PATHWAY IS UPREGULATED IN MCDS AND 
LNETS 
Increasing number of pathological conditions are been shown to have mutations in mTOR 
signaling pathway. mTOR is a serine/threonine kinase that forms two protein complexes 
(mTORC1 and mTORC2) and is involved in regulation of most cellular growth, proliferation, 
migration and metabolic processes (Crino, 2016; 2015; Bockaert and Marin, 2015; Liko and Hall, 
2015; Laplante and Sabatini, 2012; Zoncu et al., 2011; Yuan and Cantley, 2008). Activation of 
mTOR pathway is environmentally regulated and occurs in response to a wide variety of signals. 
Upon activation of mTOR pathway through RTKs or G-protein coupled receptors (GPCRs) by 
Insulin or insulin-like growth factors (IGFs) there is an increase in protein and lipid synthesis that 
may lead to increased cell size and dysmorphogenesis (McCubrey et al., 2012; Laplante and 
Sabatini, 2009; Kumar et al., 2005; Gao and Pan, 2001).  
mTOR pathway is regulated by multiple extracellular as well as intracellular signals. 
Downregulation of mTOR pathway may result from intracellular changes in oxygen and cellular 
energy levels, DNA damage (Heberle et al., 2014; DeYoung et al., 2008), and synaptic 
transmission (Ling et al., 2017; Kenney et al., 2015; Weston et al., 2012; Fraser et al., 2008; 
Tavazoie et al., 2005). Changes in those processes may signal through adenosine-monophosphate-
activated protein kinase (AMPK) (Budanov and Karin, 2008; Inoki et al., 2003) and/or regulation 
of DNA damage response 1 (REDD1) (Lipina and Hundal, 2016). Any activating upstream to 
mTOR signal requires presence of amino acids, particularly leucine and arginine, and this is 
independent of TSC1/2 complex regulation (Chantranupong et al., 2016; Wolfson et al., 2016; 
Smith et al., 2005).  




Possible activation of mTOR pathway has been previously shown in LNETs. Using single-
strand conformation polymorphism (SSCP) and sequence analysis of PCR products together with 
laser assisted microdissection of single cells Becker et al. (Table 2. 2001) described increased high 
frequency of genetic polymorphism with mostly silent or in the non-coding regions of TSC2 gene 
in 15 out of 20 dissected GG patients tissue samples (most affected are intron 4 and exon 41) and, 
additional, interesting, new somatic mutation in intron 32 of TSC2 (C.148C->T). The mutation in 
intron 32 of TSC2 was specific to glial cell population but not dysplastic neuronal cells. Additional 
findings included 7 silent polymorphisms or polymorphisms in the non-coding regions in TSC1 
gene. The finding of new somatic mutation in intron 32 of TSC2 in glial population provides a 
possible support to the hypothesis of the neoplastic transformation of glial component in GG.  
Latter study by Boer et al. (2010b) using immunocytochemistry demonstrated 
phosphoactivated protein members of mTOR pathway in 9 cases of GG. Amongst those proteins 
are pPDK1, a protein kinase upstream to AKT (in about 27% of all neurons in the field), and 
AMOG, an additional upstream activator of AKT, coincided with CD34 expression pattern. In the 
control tissue AMOG expression was restricted to perivascular astrocytes (GFAP positive). In 
DNETs, on the other hand, AMOG expression was evident in only few astrocytes. Ganglioglioma 
tissue also had relatively high expression of phosphorylated pAKT (in about 58% of all neurons 
in the microscope field). Ezrin, radixin and moesin (ERM) – actin binding proteins that are 
involved in cell adhesion and growth control and interact with TSC1 were found to be expressed 
in about 57% of all neuronal population of microscope field in GG. Phosphorylated mTOR was 
expressed in about 66% of all neurons in the microscope field. About 17% of neurons in GG were 
positive for p4EBP1, a downstream target of mTORC1. Phosphorylated eLF4G a downstream 
target of 4EBP1 was expressed in 28% of all neurons in the microscope field in GG. 




Phosphorylated S6 in 33%, pS6K-T389 in 28%, p-S6K-T229 in 25%. In contrast to GG the highest 
expression of mTOR pathway components in 9 DNET cases was for pPDK1 – about 13%, 5% for 
pS6, 2% for pS6K-T229 and 2% for pAKT. Importantly, peritumoral dissected tissue (from three 
GG and two DNETs) showed higher expression of all mTOR pathway phosphorylated components 
compared to DNETs. The neoplastic glial component of GG was not consistently immunoreactive 
to phosphorylated mTOR pathway components. Interesting that recent work by Kakkar et al. 
(2016) does show positive p-S6 and 4EBP1 staining in 89% of DNETs cases (57 patients) with 10 
to more than 50% of cells stained. The difference may lay in pre-operative invasive evaluation 
procedures, for instance, epilepsy monitoring using depth electrodes implantation that has been 
shown to phosphoactivate pS6 (Sosunov et al., 2008). It’s possible that increased “stress” to brain 
parenchyma may increase phosphoactivation of pS6, which could be differentiated by IHC for 
phosphoactivated SAPK/JNK as shown by Sosunov et al. (2008). Avoiding such confusion 
initially by examining and quantifying the staining distribution in the tissue farther away from the 
implanted electrodes may represent a possible solution with care description of tumor affected 
area.  
Samadani et al. (2007) has shown an increased activation of mTOR pathway in resected GG 
tissue. By Immunohistochemical staining against phosphorylated protein S6 of 40S ribosomal 
subunit and S6 kinase, a downstream target of mTOR, this group estimated that about 30% of all 
cells in each low magnification (X20) microscope field were positive for pS6K and pS6. Hutt-
Gabezas et al. (2013) using IHC staining against phosphoactivated components of mTOR pathway 
in formalin fixed/paraffin embedded tissue samples reported moderate to strong staining for pS6 
in 107 cases out of 177 of pediatric low-grade glioma consisting mostly of pilocytic astrocytoma 
cases (133). Additionally, those authors showed various number of cases stained positive for 




p4EBP1 (35 out of 115), pELF4G (66 out of 112), mTOR (53 out of 113), RAPTOR (64 out of 
102), RICTOR (48 out of 101), and pAKT (63 out of 103) and complete loss of PTEN (7 out of 
101).  Immunohistochemical staining showed PTEN loss in another LNET - papillary GNET 
(PGNET, 2 out of 4 cases) (Myung et al., 2011). PCR amplification of DNET dissected and 
formalin fixed tissue showed 4 out of 73 studied cases with Loss of Heterozygosity (LOH) in 10q 
of PTEN locus (Thom et al., 2011a).   
A case report using PCR analysis and literature review showed PIK3CA E545K mutation in 
one case with a mixed rosette forming glioneuronal tumor - RGNT/DNET finding (Eye et al., 
2017). These authors using Pubmed and Embase search from 1946 to November 2015 also 
reported on another six cases of RGNTs published mutations in PIK3CA: 1) E542K, and 2 cases 
of H1047R (Ellezam et al., 2012), 2) H1047R (Thommen et al., 2013), 3) E545K (Cachia et al., 
2014) 4), H1047R (Gessi et al., 2014). Fibroblast Growth Factor Receptor 1 (FGFR1) N546K 
mutation reported in RGNT by Gessi et al. (2014) using pyrosequencing and Sanger sequencing 
upon relapse also demonstrated aforementioned PIK3CA H1047R. There was one additional case 
with FGFR1 K656E mutation (initially diagnosed as pilocytic astrocytoma – PA). Overall these 
studies demonstrate significant activation of mTOR pathway either due to dysfunction of 
regulator-inhibitor (PTEN) component, increased downstream targets phosphorylation (pS6, 
pS6K, PELF4G), or presence of activating mutations (PIK3CA E545K, H1047R) in LNETs. 
 
RAS-RAF-ERK PATHWAY IS UPREGULATED IN LNETS 
Another pathway that is activated in LNETs and may have interactions with mTOR pathway 
is mitogen activated protein kinase (MAPK) pathway. MAPK pathway major components RAS-
RAF-ERK are used on par for the pathway nomenclature. RAS-RAF-ERK is one of the major 




molecular pathways involved in cell proliferation, survival/apoptosis, gene regulation, migration 
and growth. As mTOR pathway dysregulation increased recognition as a pathological cause of 
MCDs in the recent decade, the dysregulation of RAS-RAF-ERK pathway also has been linked to 
MCDs, particularly to LNETs (Hong et al., 2015; Kim and Choi, 2015; McCubrey et al., 2012; 
Lawrence et al., 2008; Roberts and Der, 2007; McCawley et al., 1999).  
Binding of the ligands (growth factors, insulin, cytokines, interleukins) to RTK results in 
recruitment of Src homology 2 domain containing adaptor protein to C-terminus of activated RTK. 
Src homology domain 2 recruits Grb2 (growth factor receptor-bound protein 2) and SOS (son of 
sevenless – a guanine nucleotide exchange factor, GEF). Son of sevenless is a homolog protein 
that loads the membrane bound GDP:GTP exchange protein (GTPase) Ras with GTP.  Ras then 
recruits the serine/threonine kinase Raf to the membrane where it becomes activated. Raf 
phosphoactivate mitogen activated protein kinase kinase-1 (MEK1), that in turn phosphoactivate 
extracellular-signal regulated kinase 1/2 (ERK1/2). Phosphoactivated ERK1/2 has more than 
hundred substrates. Amongst its activation targets are transcription cellular machinery - P90 
ribosomal six kinase-1 (P90RSK1), that activate cAMP response element binding protein (CREB)) 
in the nucleus. ERK1/2 also activates translational process through P90RSK1 activation of MAPK 
signal integrating kinases (Mnk1/2), that activates eukaryotic translation initiation factor 4E 
(ELF4B).Also ERK1/2 activates P70 ribosomal S6 kinase (P70S6K), which phosphoactivates 
Ribosomal Protein S6 (PS6)) in different cellular compartments (Pernice et al., 2016; McCubrey 
et al., 2012; Xing et al., 1996). Additionally, ERK1/2 exerts multiple inhibiting feedback loops 
with different components of RTK-RAS-RAF-ERK pathway to prevent its activity. Some of the 
examples are described here. ERK1/2 can loop back on another member of RAF family - CRAF 
either activating it or inactivating it depending on the site of phosphorylation (Sturm et al., 2010; 




Balan et al., 2006; Dougherty et al., 2005). It can phosphoinhibit MEK1 (Catalanotti et al., 2009), 
and cause dissociation of SOS/Grb2 complex from tyrosine phosphorylated sequences that 
prevents Ras activation (Buday et al., 1995). ERK1/2 can also phosphoinhibit RTK (Li et al., 
2008b), or induce dual specificity phosphatases (DUSPs) transcription  that serves as a negative 
regulators of RAS-RAF-ERK pathway (Ekerot et al., 2008).   
Activating mutations in RAS-RAF-ERK pathway are found in multiple components including 
the RTKs in LNETs (Stone et al., 2017; Rivera et al., 2016; Blumcke et al., 2014; Thom et al., 
2012). Here are described few recent cases as an example of most frequent mutations.  Chappe et 
al. (2013) using PCR-high resolution melting (PCR-HRM) with Sanger sequencing and IHC 
showed retrospectively BRAFV600E activating mutation in about 30% of DNETs, 38.7% of GG, 
12.5% of PA and 60% of PXA.   Using IHC Koelsche et al. (2013) showed that 58% of GGs have 
stained positive for BRAFV600E clone VE1 specific antibody. This was further confirmed by 
Sanger sequencing in DNA available samples with 32 out of 34 VE1 positive tumors.  Dahiya et 
al. (2014) using VE1 IHC showed positive staining for BRAFV600E in 38% of GGs.  
BRAFV600E mutation represent the most frequent mutation in LNETs with up to 70% of cases 
(Prabowo et al., 2014; Schindler et al., 2011). Additionally, BRAF copy number increase was 
shown in 33% of DNETs (Kakkar et al., 2016). Fusion with KIAA-1549 gene arising from tandem 
duplication of about 2 Mbp fragment of chromosome 7q arm producing protein with N-terminus 
of KIAA-1549 and BRAF kinase domain, was shown in about 70% of PA cases (Collins et al., 
2015; Jones et al., 2013). In a few cases, fusion with other genes that resulted in the loss of 
regulatory N-terminus and retention of BRAF kinase domain was reported as well: FAM131B, 
RNF130, CLCN6, MKRN1, GNAI1, QKI, FZR1, and MACF1 (Jones et al., 2013; Zhang et al., 
2013; Cin et al., 2011). Interestingly, alterations (insertion of three amino-acids 




p.Arg506_insValLeuArg)  that stabilize dimeric form of BRAF, which is active independent of 
Ras stimulation, has been shown to increase pERK1/2 signal comparable to BRAFV600E mutation 
in NIH3T3 cells (Jones et al., 2013)   
Other driver mutations (McCubrey et al., 2012) in RAS-RAF-ERK pathway in LNETs include 
RTK (Fibroblast Growth Factor Receptor 1: FGFR1) N544K, N546K, K656E, R659L (Qaddoumi 
et al., 2016; Jones et al., 2013). Alteration in autophosphorylation results in higher kinase activity 
increasing RAS-RAF-ERK activation, which probably works through its substrate FGF2. 
Alterations in RAS (KRAS), the same allele affecting E63K + R73M and L19F + Q22K mutations 
was described in two different cases of PAs (Jones et al., 2013). CRAF alterations include 
SRGAP3-CRAF fusion in PAs that leads to increased kinase activity of the product (Jones et al., 
2009). Activating mutations in the platelet-derived growth factor receptor α (PDGFRα) K385I and 
K385L were reported in 2 LNETs, 1 DNET, and 1 oligoastrocytoma (Qaddoumi et al., 2016). New 
fusion of genes SLMAP-NTRK2 (sarcolema associated protein-neurotrophic receptor tyrosine 
kinase 2) was found in GG (Qaddoumi et al., 2016). Passenger mutations and mutations in genes 
found in more aggressive tumors are not discussed here. 
 
RAF ONCOGENES AND PROTEINS FUNCTION IN DESEASE. 
Of the RAS-RAF-ERK pathway alterations, the RAF oncogene subfamily of serine/threonine 
kinases elicit the most interest. A single missense somatic mutation in BRAFV600E and multiple 
BRAF fusions has been found in different pathophysiological conditions, specifically  in up to 
70% of LNET cases (Ballester et al., 2017; Chasseur et al., 2017; Ko et al., 2017; Lee et al., 2017; 
Oishi et al., 2017; Vanden Borre et al., 2017; Domingo and Schwartz, 2016; Kakkar et al., 2016; 
Prabowo et al., 2014; Koelsche et al., 2013; Cin et al., 2011; Schindler et al., 2011).   




RAF GENE FAMILY PROTEINS AND MOLECULAR INTERACTIONS. 
The mammalian RAF (Rapidly Accelerated Fibrosarcoma) gene family consist of three 
genetically independent isoforms: ARAF, BRAF and CRAF (also RAF-1). ARAF is located on 
the sense strand of chromosome Xp11.2-p11.4, depending on the sequence source 
(GCID:GC0XP047562). BRAF is on the antisense strand of 7q34 (GCID:GC07M140719) and 
CRAF is on the antisense strand of 3p25.2-3p25 (GCID:GC03M012583). All three RAF proteins 
are activated by Ras-GTP binding and serve as activators of mitogen-activated protein kinase/ERK 
kinase (MEK1/2) (Papin et al., 1995b) with differential sensitivity  to RAS and Src tyrosine kinase 
phosphorylation requirement, and differences in activation potency and interaction preferences 
(Lavoie and Therrien, 2015; Hekman et al., 2002; Marais et al., 1997; Wu et al., 1996). The BRAF 
is RAS-activated, Src-independent with the highest basal kinase activity, and the most potent 
activator of MEK. While CRAF and ARAF are both Src and Ras activated and ARAF is the least 
potent activator of specifically MEK1 and not MEK2 (Wu et al., 1996). There are 21 Ras isoforms 
and only HRAS, KRAS and NRAS has been shown to activate BRAF in HEK293T cells, while 
ARAF responded also to RRAS3 and CRAF to RRAS3, RIT and TC21. This Ras isoform 
interaction with ARAF and CRAF may be cell-type dependent (Rodriguez-Viciana et al., 2004; 
Vossler et al., 1997) . 
CRAF(RAF-1) – cellular proto-oncogene was the first homolog of that family cloned in 1985 
by Bonner et al. (Bonner et al., 1985), however the first description of RAF homologue, dates to 
1983 as a retroviral oncogene, v-RAF, transduced by murine sarcoma virus (MSV) isolate 3611 
recovered from mouse that developed histiocytic lymphoma and lung adenocarcinoma (Rapp et 
al., 1983). Before 2002 CRAF was the primary focus of research of those genes family. The 
discovery of BRAF mutation in 66% of malignant melanomas and at the lower frequency in 




multiple human solid tumors (Davies et al., 2002) shifted attention to biological functions and 
biochemical interactions of that isoform.  BRAF was first identified by Ikawa et al. (1988) and is 
the phylogenetic oldest isoform that is absent in yeast and appears in invertebrates (Aken et al., 
2017; Ensembl, 2016).  
 





All RAF isoforms have 3 functionally distinctive conserved domains (CR1-3, Figure 2, 
adopted from Wan et al. (2004)). CR1 contains two RAS-GTP binding sites (RBD and CRD – 
cysteine rich domain or a zing finger structure, a secondary RAS binding site), and is involved in 
membrane recruitment, and, through CRD interaction with kinase domain in autoinhibition (Tran 
 
A BA 
2A. (numbered residues for PKA) adopted from Kornev et al. (2006) & reviewed by Roskoski (2010) 2B. is 
from Wan et al. (2004). A. Diagram of the inferred interactions between human BRAF kinase catalytic core 
residues, ATP, and MEK (the protein substrate).  Catalytically important residues that are in contact with ATP 
and MEK occur within the light khaki background. Secondary structures and residues that are involved in 
regulation of catalytic activity occur within the gray background. Hydrophobic interactions between the HRD 
motif, the DFG motif, and the aC helix are shown by black arrows while polar contacts are shown by dashed 
lines. Phos, phosphate. B. Schematic of BRAF primary structure, showing functional domains and position of 
32 observed cancer-associated mutants of BRAF. The amino acid substitutions are color coded according to 
their activity class. (Figure 4 in Wan et al., 2004) 
 




et al., 2005). CR2 when phosphorylated at inhibitory phosphorylation sites (S214 for ARAF, S259 
for CRAF and S365 for BRAF) negatively regulates RAS-GTP binding and Raf activation 
(Dhillon et al., 2002). CR3 is a kinase and phosphoactivation domain.  
BRAFV600E mutation activates BRAF kinase by mimicking phosphorylation of the activation 
segment of CR3 that releases its inhibitory interactions with the ATP binding P-loop at the same 
kinase domain (Roskoski, 2010; Kornev et al., 2006; Wan et al., 2004). Conversely, Rheb protein, 
which activates mTORC1 at the lysosome, suppresses BRAF and CRAF kinase activity through 
phosphorylation reduction of N-region of CR3 domain and subsequent disruption of dimerization 
of RAF proteins (Karbowniczek et al., 2006; Im et al., 2002).  
Although heterodimers of CRAF with BRAF are found at the lower concentrations in COS-1 
cells (about 0.3% of CRAF and 0.1% BRAF total cell pool), it occurs as a part of physiological 
activation and accounts for most of the kinase activity compared to homodimers and monomers 
Heterodimerization results in about 30-fold increase in kinase activity, functionally serving as 
additional regulatory mechanism. This heterodimerization requires intact kinase activity, is 
stabilized by binding of 14-3-3 proteins when CRAF is activated by Ras and destabilized by ERK 
feedback phosphorylation of T753 in BRAF C-terminus (Rushworth et al., 2006; Weber et al., 
2001). During heterodimerization BRAF can transphophorylate and activate CRAF given that it is 
phosphorylated at two residues (T491 and S494) in activation loop and is bound to 14-3-3 proteins.  
(Garnett et al., 2005). While BRAF wild type protein requires RAS activation of CRAF for 
dimerization - BRAFV600E induce constitutive RAS independent dimerization with CRAF in 
COS-7 cells (Garnett et al., 2005).  
Interestingly, more than 80% of mutations located either within the ATP binding P-loop or the 
activation segment, with V600 site mutations occurring in 98% of oncogenic BRAF and V600E 




mutation representing over 97% of those mutations (Lavoie and Therrien, 2015; see supplementary 
Table1 Wan et al., 2004).  
BRAF gene comprised of 18 exons and is expressed in all tissues with specifically high 
expression levels in neuronal tissue of CNS, testes and parathyroid gland  as shown by RNA-seq 
and IHC, single cell RNA-seq, as well as RT-PCR (Uhlen et al., 2016; 2015; Linnarsson, 2015; 
Zeisel et al., 2015; Barnier et al., 1995). Alternative splicing of BRAF generates 10 different 
spliceosomes in murine and 5 in human tissues, contributing to tissue specific RAS-RAF-ERK 
pathway regulation (Aken et al., 2017; Ensembl, 2016; Barnier et al., 1995). Eight out of ten 
spliceosomes are expressed in murine brain and nine in spinal cord. Two of the BRAF 
spliceosomes (containing exon 8b; and neuron specific – 10) expressed in the brain tissue at much 
higher levels than in other organ tissues (Barnier et al., 1995; Papin et al., 1995a).  
 
FUNCTION OF RAF PROTEINS THROUGH MOUSE MODELS. 
Knock-out (KO) mouse models demonstrate a differential functionality of RAF isoforms 
(Matallanas et al., 2011). CRAF complete KO has been shown to have increased apoptosis of 
embryonic tissue. Specifically, high effects were observed in the liver with hypocellularity, due to 
hepatoblasts decrease. Those mice die by mid-gestation (E11.5-13.5, 16.5), which is dependent on 
mixed genetic background (Mikula et al., 2001). Conditional placenta excluded CRAF KO did not 
have rescue effect (Galabova-Kovacs et al., 2006). Knockin mutation of the endogenous 340/341 
tyrosines to phenylalanine in CRAF, which disrupts kinase domain activity on MEK, produce adult 
mice with no apparent defects (Huser et al., 2001). This substitution results in only up to 70% 
reduction of induced activity, in which case the residual activity might be sufficient to sustain life 
and normal phenotype of affected mice (Barnard et al., 1998). BRAF complete KO results in death 




in mid-gestation (E11.5) due to vascular malformation in the placenta and could be rescued by 
conditional placental excluded KO. This was consistent with the higher expression levels of BRAF 
in embryonic placenta of E11.5 mice, while CRAF showed higher expression levels in embryo 
proper and ARAF was equally expressed in embryo proper and the placenta  (Galabova-Kovacs et 
al., 2006). The BRAF KO mice also have a substantial growth deficits and neuronal defects at 
E10.5 that are not attributed to developmental arrest (Galabova-Kovacs et al., 2006; Wojnowski 
et al., 1997). Interestingly, conditional knockin mouse model of BRAFV600E mutation also cause 
embryonic death by gestational day E7.5. At even low expression levels under the control of IFN-
inducible promoter in the mouse are lethal with overall survival up to post-natal day P28 (Mercer 
et al., 2005). This indicates that deregulation of BRAF activity in growth and development is 
detrimental for survival. ARAF KO survive within the range of P7 to P21 exhibiting a wide 
neurological and intestinal pathologies. This is also genetic-background dependent, with C57Bl/6 
background producing lethal young mice and when bred on 129/OLA background producing adult 
mice that has neurological defects (Pritchard et al., 1996).    
The oncogenic potential of all three RAF isoforms is also different. CRAF and ARAF 
mutations are rare in human cancers (Rebocho and Marais, 2013; Zebisch et al., 2006; Emuss et 
al., 2005; Lee et al., 2005), while BRAF mutations has been established as a primary oncogene 
(Davies et al., 2002). Although overactivated CRAF in tissue-specific manner in transgenic mice 
under SP-C promoter can cause lung adenoma (Kramer et al., 2004; Kerkhoff et al., 2000) and  its 
overexpression also found in a variety of human cancers, such as lung, liver, prostate, myeloid 
leukemia and head and neck squamous cell carcinoma (Mukherjee et al., 2005; Riva et al., 1995; 
Schmidt et al., 1994), current theory suggest a mediating RAS and RTK overactivation role for 
CRAF (Dumaz et al., 2006; McPhillips et al., 2006; Zebisch et al., 2006; Emuss et al., 2005; Porter 




and Vaillancourt, 1998; Miwa et al., 1994). Considering scarce findings of CRAF mutations in 
naturally occurring cancers on one hand and CRAF overexpression found in some cancers on the 
other hand, more thorough examination is required to exclude the possibility of the allelic 
alterations and random mutations in cases with overactivated CRAF and to determine its role in 
oncogenesis.  Rare ARAF mutations in cancer and their kinase inactivating nature suggest a 
passenger mutation or signaling specific context (Rebocho and Marais, 2013).  
 
OTHER PATHWAYS, GENES AND CHROMOSOMAL 
ALTERATIONS IN LNETS 
Previous studies have shown multiple alterations in PIK3CA-AKT3-mTOR and RAS-RAF-
ERK pathway leading to their aberrant activation in LNETs, however in few cases other pathways 
which may interact with the aforementioned ones are pathologically altered. Additionally, multiple 
studies suggest that global gene expression is altered and possible chromosomal reorganization 
happens in LNETs (Qaddoumi et al., 2016; Prabowo et al., 2015; Aronica et al., 2008a; Fassunke 
et al., 2008; Hoischen et al., 2008; Becker et al., 2006).  
One of the additional altered pathways in GG is the reelin pathway that is involved in neuronal 
development, migration, morphogenesis, neuronal plasticity and neurodegeneration (Bock and 
May, 2016; Ishii et al., 2016; Lee and D'Arcangelo, 2016; Sekine et al., 2014). Kam et al. (2004) 
showed one case of mutation/polymorphism in p35 gene (L302I) and overall lower expression 
levels of two major components of the reelin pathway p35 (21%) and dab1 (28%) (disabled-1) in 
GGs compared to controls of normal brain tissue with equivalent parts of white and grey matter. 
The protein encoded by p35 is an activator of cyclin-dependent kinase-5 (CDK5), another 
important component of the reelin pathway. Earlier Becker et al. (2002) showed lower expression 




(mRNA levels normalized to GAPDH) of CDK5 (55%) and another major component of the reelin 
pathway - doublecortin (DCX, 30%) in GGs tumor tissue samples compared to epilepsy patients 
without MCDs. CDK5 functions in neuronal maturation and migration and many more other 
essential biochemical processes (Dhavan and Tsai, 2001). DCX is a phosphoprotein that is 
associated with microtubules and responsible for neuronal maturation, migration and cytoskeletal 
stabilization during neurite outgrowth (LoTurco, 2004).  
Fusion of nuclear phosphoprotein transcription factor MYB involving mostly exon 15, but in 
some cases also exon 9 to QKI RNA-binding protein gene at exon 5 was found in 41% of diffuse 
astrocytomas (DA), and 87% (13/15) of angiocentric gliomas by whole-exome-sequencing (WES), 
whole-genome (WGS) and transcriptome sequencing (RNA-seq) (Qaddoumi et al., 2016). Using 
Sanger sequencing for hot-spot mutation analysis wuthors showed one DA case with h3 histone 
family member 3A (H3F3A) K27M mutation, which is involved in formation of nucleosome 
structure of chromosomal fiber. Authors also reported of IDH1/2 mutation that was found in 4 out 
of 20 diffuse oligodendroglial tumors (d-OT), new fusion of genes in GGs – EWSR1-PATZ1 
(EWS RNA binding protein 1- POZ/BTB and at hook containing zink finger 1). In the same study 
additional frequent genetic alteration was found in d-OTs - chromosome 1p/19q co-deletion.  
Gain of chromosomes 5 (16-18%), 7(21-23%), 6 (10%), 8 (13%), 12 (12%); and loss of 22q 
(16%), 9(10%), 10 (8%) mostly in glial components was found in GGs and DNETs. With gain of 
chromosome 5 been the most frequent finding in GGs (Prabowo et al., 2015; Hoischen et al., 2008). 
However, Prabowo et al. (2015) found no correlation of chromosomal 5,7 and 6 gains to DNETs 
and GG IHC features or clinical data. Hoischen et al. (2008) using unsupervised cluster analysis 
also showed separation of GGs into two subgroups, one with complete gain of chromosome 7 
combined with 5, 8 and 12 and the other with loss of chromosome 9 and 22q, although the 




alterations found in the second subgroup are not exclusive to it. Interestingly, methylation profiling 
with principle-component analysis of 91 samples of LNETs showed segregation of genetic 
mutation subtypes into four distinct groups - adult-type glioma, BRAF, FGFR1, MYB/MYBL1 
pathologies (Qaddoumi et al., 2016).  Supporting the finding of BRAF and FGFR1 groups 
segregation, another study using DNA methylation arrays combined with RNA sequencing of 111 
samples from GG, DNET and non-specific glioneuronal tumors showed two distinct groups, one 
with astrocytic differentiation and is driven by BRAF mutations, while the second group displayed 
oligodendroglial differentiation driven by FGFR1 mutations (Stone et al., 2017) 
Gene expression analysis using U133 plus 2.0 microarray with 38,500 human genes spanning 
54,000 probe sets identified 2874 overexpressed and 3255 underexpressed probes at p<0.01 and 
false detection rate of 3.9% (each probe has a 3.9% chance of been false positive) in 4 GGs 
compared to 3 fresh autopsy acquired control samples (Aronica et al., 2008a). Aronica et al. 
(2008a) showed that immune and inflammatory genetic mechanisms were the most increased in 
GGs - numerous interleukins, TGF, Toll-like receptor pathway and T-cell receptor signaling 
pathway, multiple complement pathway genes, and coagulation cascade genes together with cell 
adhesion and extracellular matrix genes like laminin, collagens, thrombospondins, CD9, CD44. 
Angiogenesis genes were also increased.  The authors also showed fivefold increased expression 
of GFAP and vimentin, indicative of reactive astrocytosis in GGs. Increased expression of cyclin 
D1, D2 and cyclin-dependent kinases 4 and 6 (CDK4 and 6) while decreased CDK5 and its 
regulatory subunit – P35 and deregulated Wnt signaling pathway that controls cell fate and cycle 
confirms abnormal cell development in GGs. Surprisingly genes associated with synaptic 
transmission and neuronal excitability represented the most prominent underexpressed group -  
decreased Voltage-Gated Potassium Channels was concurrent with decreased calcium channel 




auxiliary subunits and some sodium channels auxiliary subunits underexpression. Interestingly 
though that SCN9A that encodes Nav1.7 and SCN7A were overexpressed in GGs. Multiple GABA 
receptor subunits together with gephyrin, a protein assisting in post-synaptic clustering were also 
underexpressed. Additionally, increase in expression for sodium-potassium co-transporter NKCC1 
and decrease in potassium-chloride co-transporter KCC2 indicate possible change in GABARs 
modulation of neuronal excitability (Aronica et al., 2008a). To avoid inter-patients’ genetic 
variability Fassunke et al. (2008) using adjacent normal cortical samples from 6 GG patients and 
7 DNETs and transcriptome-wide expression on U133A microarray analysis showed a differential 
expression of 94 genes with affected chromatin state and transcription factors, Intracellular and 
extracellular signal transduction, cell adhesion, cell cycle and proliferation, development and 
differentiation.   
Gain on chromosome 3p26.2-p26.3 encompassing two activating ligands of notch - CNTN6 
and CNTN4 suggest a possible dysregulation of this signaling pathway in GGs (Hoischen et al., 
2008). Notch-signaling pathway play important role in embryogenesis and cortical development  
(Carrieri and Dale, 2017) The presented  examples of chromosomal and genetic alterations in 
LNETs provide a significant amount of information about those changes and demonstrate 
importance of further organization, classification and elucidation of epileptogenic mechanisms of 
subgroups of LNETs for development of personalized treatment approach (Blumcke et al., 2016; 








1.3 EXCITABILITY MECHANISMS CONTRIBUTING TO 
EPILETOGENESIS IN MCDS AND LNETS. 
Heterogeneity of LNETs may also point to multiple different molecular mechanisms 
responsible for epileptogenesis. Considering that LNETs are the second most frequent pathology 
finding in surgically treated adult patients after HS, and in children after FCD, it is necessary to 
find their primary causes. The genetic aberrations and the associated pathological hyperexcitability 
and hypersynchrony mechanisms have a direct link to epilepsy. Investigation of those mechanisms 
may further contribute to improvement of patients’ treatment with purpose of developing targeted 
personalized therapy with minimal effect on their quality of life. The next section discusses current 
theories of epileptogenic mechanisms in LNETs and MCDs.  
 
PROLIFERATION, MIGRATION, DIFFERENTIATION AND CELL 
GROWTH 
Cortical hexalaminar formation is a tightly regulated process. Initial proliferation of neuronal 
stem cells (NCS) in the ventricular zone (VZ), asymmetric and symmetric division, differentiation 
to radial glia in mid-gestational period (E33 in humans and E10.5 in rodents), and migration along 
the radial glia axis, or tangential migration from ganglionic eminence (GE) of interneurons to 
appropriate cortical laminae creates complex cortical structure. Glial and neuronal cells originating 
from radial glia progenitors pool, generating synaptic contacts with subcerebral and thalamic areas 
and function to create different sensory modalities and complex social behavior (Lim and Alvarez-
Buylla, 2016; Breunig et al., 2011; Bystron et al., 2008; Molyneaux et al., 2007; Kriegstein and 
Parnavelas, 2003; Rakic, 2003). Interruption of this intricate process during proliferation leads to 




changes in cell composition, size, dyslamination and synaptic connections (Roy et al., 2015; 
Alkuraya et al., 2011; Bakircioglu et al., 2011). Disrupted migration keeps cells from reaching 
designated laminae (Chew et al., 2013; Cushion et al., 2013; Poirier et al., 2010). Inappropriate 
differentiation and growth leads to alterations in a post-synaptic neurotransmitter receptors and 
changes in intrinsic excitability properties (Judkins et al., 2011; Andre et al., 2010; Andre et al., 
2004; Cepeda et al., 2003; Crino et al., 2001). This may lead to neuronal networks with lower 
threshold for seizure generation.  
Changes in neuronal and glial cell populations may stem from reduced proliferation or 
increased apoptosis, increased proliferation or decreased apoptosis, and/or abnormal proliferation. 
The molecular pathways that are involved in cell cycle progression and DNA repair, and 
subsequently affect neurogenesis and gliogenesis are altered in disorders with presumed defects in 
proliferation of progenitor cell population, like FCD II, TSC, HME, ME, GG, microcephaly. 
(Parrini et al., 2016; Blumcke et al., 2014; Barkovich et al., 2012).  The mechanisms of 
epileptogenicity in abnormal proliferation MCDs is less clear. The suggested mechanisms are 
abnormal synaptic contacts with increased excitatory neurons and decreased inhibitory 
interneurons content, and support of the network with increased seizure susceptibility by astroglial 
dysplastic cells (Andre et al., 2004; Crino et al., 2001; O'Connor et al., 1998; Cornell-Bell et al., 
1990). Additionally, current theory suggests that epileptogenicity source may arise outside the 
malformation foci, or be independent of cortical malformation (Maynard et al., 2017; Roy et al., 
2015; Kohling et al., 2006; Patt et al., 2000).  
Migrational defects may arise from injury to ventricular zone epithelium (migration start point) 
or pial limiting membrane that cause detachment of radial glia and disruption of migratory 
pathway. Included in these group are different types of heterotopia, lisencephalies, cobblestone 




malformations (Parrini et al., 2016; Barkovich et al., 2012).  Interesting that in periventricular 
nodular heterotopia expression of layer specific markers shows that the heterotopic population of 
migrating neurons is the early one. The neurons that designated to populate layers 6 (Rorβ) through 
4 (Nurr1) are the ones that forms this malformation (Garbelli et al., 2009). The mechanisms of 
epileptogenicity is not clear in those disorders as well, with similar hypothesis of synaptic 
dysregulation and probably dyslamination independent seizures (Farhan et al., 2017; Diaz-Alonso 
et al., 2016; Hsieh et al., 2016). 
Injury to the brain that happens after the cell migration period is ended may disrupt cortical 
cytoarchitecture and cause FCDI or in some instances FCDIII, polymicrogyria and schizencephaly 
(Barkovich et al., 2012). In those disorders the epileptogenicity mechanisms are also not known. 
 
1.4 HISTOPATHOLOGICAL FEATURES AND THEIR 
HYPEREXCITABILITY IN MCDS AND LNETS 
Shared histopathological features in MCDs with LNETs may be the source of ictogenesis and 
subsequent epileptogenesis. Following sections presents common features and their possible 
contribution to neuronal and network hyperexcitability. 
DYSMORPHIC CYTOMEGALIC NEURONS 
Dysmorphic cytomegalic neurons in resected human brain tissue have a range of 16-43 µm 
diameter of the soma compared to 12-25 µm in normal-appearing pyramidal neurons in layer 3, 
tortuous processes and presumed to represent inappropriate differentiation and growth and almost 
always co-occur with cortical dyslamination. Those dysmorphic cytomegalic neurons were 
suggested to be the source of epileptogenicity (Cepeda et al., 2006; 2005; 2003). Those neurons 
are present in FCD Type II, hemimegalencephaly (HME), TSC, GG, complex DNETs, diffuse 




DNETs and mixed DNETs, lack in FCD Type I (Crino, 2013; Thom et al., 2012; Blumcke et al., 
2011; Thom et al., 2011b; Palmini et al., 2004) and simple DNETs (Thom et al., 2011b). In this 
case other morphologically and altered components and/or cortical structure disruption, for 
instance – immature, misoriented neurons and dyslamination may be the source of epileptogenesis. 
Increased excitability of dysmorphic cytomegalic cells may be due to increased L-type Ca2+ 
conductance (Cepeda et al., 2003). Relatively hyperpolarized resting membrane potential and 
reduced postsynaptic receptors densities in dysmorphic cytomegalic neurons contradict the 
hypothesis of those cells been epileptogenic source. Additionally, as it has been shown in FCD 
patients, ECoG ictal zone and interictal spiking zones were the least expected location for 
dysmorphic neurons to be found after resection. Cortical regions enriched in dysmorphic neurons 
displayed background high voltage slow rhythmic waves, while FDG-PET/MRI showed 
thickening of cortical area (pachygyria). Although those findings indicate that dysmorphic 
cytomegalic neurons are less likely to be the epileptogenic source, their presence correlated with 
CD severity and worst ECoG scores (Cepeda et al., 2005). Possible alterations in molecular 
mechanisms that may cause hyperexcitability in dysmorphic neurons is increased Pannexin 1 
expression shown with Western Blot and immunohistochemistry in resected brain tissue from FCD 
IIa and IIb patients (Li et al., 2017). Dysmorphic cytomegalic neurons were shown to have 
decreased Mg2+ sensitivity of postsynaptic NMDA receptors due to altered, dysmature receptor 
subunit composition (Andre et al., 2004). Cytomegalic neurons from FCD II showed increased 
GABA induced peak currents, but decreased current densities. The GABA induced currents had 
longer kinetics and decreased sensitivity to zolpidem and zinc compared to non-dysplastic tissue 
and FCD I resected tissue pointing to different subunit composition of GABAA receptors or 
delayed clearance of GABA from synaptic cleft (Andre et al., 2008) 




In support of dysmature brain development hypothesis (Cepeda et al., 2007; 2006), where 
seizures may result from interactions of dysmature cells with normally developed and properly 
migrated pyramidal cells, cytomegalic interneurons may also be hyperexcitable and contribute to 
ictal discharges (Andre et al., 2010; Andre et al., 2008; Andre et al., 2007; Avoli et al., 2005). 
GABAA mediated chloride driven synaptic currents may switch from inhibition (Cl
- influx) to 
excitation (Cl- efflux) in GG, HME, FCD Type I and Type II, TSC and HS with medial temporal 
lobe epilepsy (MTLE) due to increased expression of Na+ K+ -2Cl- cotransporter - NKCC1. This 
NKCC1 cotransporter increases the internal chloride concentration. Additionally,  
decreased/altered expression of K+ - Cl- cotransporter, KCC2 that extrudes Cl- outside the cell 
based on established K+ gradient by Na+/K+ ATPase pump was also reported in the aforementioned 
disorders (Puskarjov et al., 2014; Talos et al., 2012; Jansen et al., 2010; Aronica et al., 2007; 
Munakata et al., 2007; Cohen et al., 2002). Support to the dysmature brain development hypothesis 
was also shown in immunohistochemical study of resected brain tissue from FCD Type II patients 
with clustering of parvalbumin (PV) and GAD stained terminals around cytomegalic neurons 
(Andre et al., 2008; Spreafico et al., 2000). In those studies, however, the overall PV and GAD 
staining was reduced in the examined specimens. It is not known if cytomegalic interneurons 
release more than one type of neurotransmitters. 
 
IMMATURE MISORIENTED NEURONS 
Immature misoriented neurons are relatively scarce, and more frequently found in young 
patients with severe FCD. Those neurons have a diameter of less than 18 µm and soma area of less 
than 250 µm2, have underdeveloped dendritic arbors with relatively few spines, and frequently 
observed in vertically oriented microcolumns in FCD Type Ia (Blumcke et al., 2011; Hildebrandt 




et al., 2005; Palmini et al., 2004; Cepeda et al., 2003). In FCD Ia immunohistochemistry showed 
that Pannexin 1 was distributed in microcolumn organized neurons, in FCD IIa and IIb it was 
shown in dysmorphic neurons, balloon cells and reactive astrocytes. Pannexin 2 levels were 
increased only in FCD IIb (Li et al., 2017). Quantitative RT-PCR and western blot analysis showed 
increased mRNA expression and protein levels of Pannexin 1 in the resected brain tissue of FCD 
Type Ia, FCD IIa, and FCD IIb patients compared to autopsy controls (Li et al., 2017). Pannexin 
1 is a large pore ion channel, which is involved in release of multiple signaling molecules like 
Ca2+, glutamate, arachidonic acid and ATP (Aquilino et al., 2017). Although Pannexin channels 
may both enhance and reduce seizure susceptibility the current data mostly in animal models with 
one study of resected brain tissue from Rasmussen syndrome patients suggest that blocking 
Pannexin channel is anticonvulsant (Aquilino et al., 2017; Cepeda et al., 2015). Immature 
misoriented neurons also receive strong rhythmic depolarizing GABAergic input (Cepeda et al., 
2003).  
BALLOON CELLS 
Balloon cells are categorized by their large cytoplasm to nucleus ratio, pail eosinophilic 
appearing on H&E staining, lack of Nissl substance, with frequent finding of multinucleated forms. 
They are not specific to any cortical area or location and are often found in an underlying white 
matter. They can be found in small aggregates and within a “normal” brain tissue.(Blumcke et al., 
2011). Intermediate neuronal filaments – vimentin and nestin that are more characteristic of 
progenitor cells and radial glia in neuroepithelium are frequently accumulate in balloon cells. 
Those cells are less frequently stained with GFAP (Urbach et al., 2002). The lack of extensive 
processes and electrophysiological neuronal features – no action potential generation, no synaptic 
inputs, suggest that they are not the “pacemaker” of epileptogenic activity, nor they able to sustain 




it. However, their more glial morphology shows that they may be the source of extrasynaptic 
glutamate that contributes to epileptogenicity of the proximal cortical region (Cepeda et al., 2006). 
Additionally, their presence in cortical circuitry may disrupt “normal” synaptic contacts and create 
aberrant hyperexcitable neuronal networks.  
 
1.5 CHANGES OF INTRINSIC NEURONAL 
EXCITABILITY MECHANISMS IN MCDS 
Neuronal intrinsic excitability – ability to fire action potential, either spontaneously or in 
response to synaptic inputs is dependent on both “passive” as well as “active” cell 
electrophysiological properties.  The mode of firing – bursting, anode break excitation 
(hyperpolarization induced rebound depolarization and AP firing), depolarization block and non-
adapting high frequency firing are probably more dependent on “active” electrophysiological 
properties. Those active electrophysiological properties include channel densities and their 
distributions and channel gating properties - activation, inactivation, and voltage-dependence of 
the latter. Additionally, ion concentration inside and outside the cell and changing voltage “driving 
force” helps to establish resting membrane potential and contribute to the activation or inactivation 
of ion conductances  (Bean, 2007). Passive electrophysiological properties of the cell include 
resting membrane potential (RMP), which is also established upon electrochemical equilibrium of 
all ions inside and outside the cell, membrane capacitance (Cm), input resistance (Rin) and 
membrane time constant (τm). More depolarized RMP makes reaching AP voltage threshold, after 
which the cell fire AP, easier. Increased Rin shows that to reach the same AP voltage threshold the 
cell will require smaller depolarizing input current (Im). And shorter τm and smaller Cm allows 




faster Cm charge and faster response of ion channels to changing voltage affecting the speed of AP 
propagation.  
 
PASSIVE PROPERTIES CHANGED IN MCDS  
Group of Cepeda et al. (2014; 2012; 2010; 2007; 2005; 2003; Andre et al., 2007) showed that 
different populations of cells in MCD resected tissue from a cohort of young patients (FCD I, II, 
III, FCD with HME, Heterotopia, TSC, and TSC alone ages 0.19-14 years) have distinctive 
electrophysiological properties. Average membrane capacitance was significantly larger in 
cytomegalic neurons (309-397 pF), cytomegalic interneurons (290 pF, N=8) and in balloon/giant 
cells (217-269 pF) compared to neighbor “normal” pyramidal neurons (132-194 pF). At the same 
time immature small neurons had smaller capacitance (64,77 pF). Input resistance was much 
higher in immature cells (607,479 MΩ) and “normal” interneurons (329,523 MΩ), and smaller in 
cytomegalic neurons (50-71 MΩ) and cytomegalic interneurons (45, N=8) (Andre et al., 2007), it 
was only higher in balloon cells in two publications, described initially as atypical cells (553 MΩ, 
N=24) in (Cepeda et al., 2003) and balloon cells (also 553 MΩ, N=22) in (Cepeda et al., 2005), 
which may be misclassification of different abnormal type of cells; latter work from the same lab 
showed comparative to normal input resistance in balloon cells (148-210 MΩ) (Cepeda et al., 
2012; 2010). Membrane time constant, τm, was significantly longer in dysmorphic neurons (4.5 
ms, N=12), cytomegalic neurons (4.5-5 ms), cytomegalic interneurons (4.2 ms, N=8), and balloon 
cells (2.9-3.6 ms), shorter in immature neurons (0.9,1ms) and “normal” interneurons (0.9,1.1ms).  
On the other hand, RMP was more hyperpolarized in cytomegalic neurons (-65 - -71 mV) 
compared to “normal” pyramidal neurons (-55 - -70 mV)  (Cepeda et al., 2012; 2010; 2005; 2003; 
Andre et al., 2007). RMP in balloon cells (-57 mV, N=24) was depolarized and comparable with 




the “normal” pyramidal neurons (Cepeda et al., 2005). Interestingly newer work from the same lab 
shows balloon cells with more hyperpolarized RMP (-74 mV, N=47) in resected tissue samples 
from TSC patients, with one example of balloon cell from FCD IIb patient displaying more 
depolarized RMP (Table. 2 & Figure 3D. Cepeda et al., 2012). Comparing FCD II with TSC 
resected tissue, Cepeda (2012) also showed that cytomegalic neurons were more frequently found 
in FCD, while balloon/giant cells were more frequent finding in TSC, also balloon cells in FCD II 
were closer to the white matter than in TSC. The differences in passive electrophysiological 
properties were not observed in previous publications, which characterized mostly “normal” 
pyramidal neurons (Cepeda et al., 1999; 1993; 1992; 1991; Tasker et al., 1996; Dudek et al., 1995; 
Wuarin et al., 1990) 
 
ACTIVE PROPERTIES CHANGED IN MCDS 
In the previous electrophysiological studies of resected CD-tissue no abnormal firing patterns 
were found in examined cells, however in most cases only “normal” pyramidal cells were 
examined (Tasker et al., 1996; Dudek et al., 1995; Wuarin et al., 1990). In studies that did examine 
abnormal cells, no differences were found in firing frequencies between cytomegalic and “normal” 
pyramidal neurons from FCD II. Additionally, cytomegalic neurons did not generate spontaneous 
AP firing in whole-cell current clamp.(Cepeda et al., 2005). The authors suggested that Inspite of 
these cells been capable of exciting neighboring neurons thus amplifying seizure activity they are 
not hyperexcitable enough to initiate seizures. On the other hand, cytomegalic inhibitory 
GABAergic interneurons displayed spontaneous AP firing and rhythmic bursting upon 
suprathreshold depolarization in current-clamp, which may synchronize neuronal activity thus 
initiating seizures (Andre et al., 2007). The balloon cells also did not display any hyperexcitability 




and did not fire AP upon application of any depolarizing current steps from -500 pA to 500 pA. 
Immature small pyramidal neurons in resected CD-tissue were suggested to be a possible 
hyperexcitable candidates (Cepeda et al., 2007) with a single example of a current-clamp recorded 
cell responding to lower rheobase with higher firing frequency of smaller amplitude APs. Normal 
pyramidal neurons in TSC resected cortical slices did not show significant changes in the firing 
frequencies (Cepeda et al., 2010). In the TSC1 Cre-mediated post-natal knockout mouse model in 
acute slices in hippocampal CA1 pyramidal neurons the rheobase, AP voltage threshold and 
latency to the first spike were increased and the AP firing frequencies were decreased compared 
to control neurons. The authors suggested that this was the result of a decreased input resistance 
and increased membrane capacitance  (Bateup et al., 2013). Earlier Wang et al. (2007) showed that 
there were no differences in firing frequencies and AP properties between the control tissue and 
TSC1 synapsin1-Cre driven knockout normal appearing pyramidal neurons. Although there was 
an increase in SAG and rebound excitation that was not quantified. 
Cumulative study over five years (Cepeda et al., 2003) showed that peak mixed Ca2+ 
conductances were significantly increased in cytomegalic neurons (4,008 pA, N=22, compared to 
1,666 pA, N=183 in “normal” pyramidal neurons), with about 60% of current flow through L-type 
Ca2+ channels, and other 40% through P/Q (25%) and N (15%) types. No active ion conductances 
were detected in balloon cells.  Andre et al. (Figure 5B. 2007) noted a delayed inward rectification 
(SAG) in interneurons in current clamp mode upon hyperpolarizing current pulse, which is 
indicative of hyperpolarization activated depolarizing current (Ih).  
Inspite of those findings intriguing question of how the epileptic seizures are generated remains 
unanswered. The possible epileptogenic source - the cytomegalic dysmorphic neurons are found 




only in about 60% of child FCD cases (Cepeda et al., 2006), which cannot explain epileptogenesis 
in remaining 40% of cases.  
 
1.6 CHANGES OF SYNAPTIC EXCITABILITY IN MCDS 
AND LNETS 
Multiple Immunohistochemical and electrophysiological studies in FCDs, TSC, HME and 
LNETs showed altered synaptic receptors densities, subunit composition that suggest possible 
immature properties of malformed components. The following sections present representative 
studies on alterations in synaptic mechanisms in MCDs and LNETs. 
 
ROLE OF GABA RECEPTORS IN MCDS 
Alterations in inhibitory and excitatory circuits have long been suggested as one of the possible 
pathophysiological mechanisms in epilepsy (Spreafico et al., 1998a; Marco et al., 1996; During et 
al., 1995; DeFelipe et al., 1994; 1993; Wolf et al., 1994; Dichter and Ayala, 1987; Lloyd et al., 
1986; Ribak et al., 1979; Van Gelder et al., 1972). First investigated by Ferrer et al. (1992) in tissue 
from FCD patient and latter (Ferrer et al., 1994) in a mixed group of patients that included patients 
with neoplasms (not specified) and FCDs showed a decrease in parvalbumin, calbindin D-28K and 
somatostatin positive interneurons in the necrotic area but not in the dysplastic area. There was 
also selective to the neoplasm affected cortical area decrease in parvalbumin and calbindin D-28K 
immunoreactivity. Latter study in FCD II showed patchy reduction in PV and calbindin 
immunostaining in dysplastic tissue with islets of positive cells throughout all cortical layers 
compared to localized to layers II/III positive staining in non-FCD control tissue  (Calcagnotto et 
al., 2005). In nodular heterotopia, FCD I, and IIb the changes in expression of postsynaptic 




receptors showed that there was a reduced number of parvalbumin (PV, chandelier and basket cells 
marker) and glutamic acid decarboxylase (GAD, enzyme that catalyzes conversion of glutamate 
to GABA) positive interneurons and interneuronal terminals. In FCD IIb the cytomegalic neurons 
were surrounded by clusters of PV and GAD positive neuronal terminals. The authors also reported 
reduced number of GABA-transporter 1 (GAT1, transports GABA from synaptic cleft into 
neurons) staining in FCD IIb. (Andre et al., 2010; 2008; Spreafico et al., 2000; 1998a; 1998b). In 
FCD I there was reduced staining of PV, GAD and patchy distribution of GAT1 and no clusters 
of PV and GAD (Spreafico et al., 2000), which was shown statistically insignificant in the latter 
studies (Andre et al., 2010; 2008). Interestingly in tissue from TSC patients there was an increased 
PV staining and positive for GAD staining in 30% of cases of TSC-like lesions as reported by 
Wolf et al. (1994). Increased decay kinetics of spontaneous inhibitory post-synaptic currents 
(sIPSCs) in (Calcagnotto et al., 2005) suggest that there is an alteration in GABA reuptake in 
FCDII. Decrease in overall PV positive terminals was seen in FCD II except giant neurons located 
in the white matter, which were surrounded extensively by PV positive terminals (Alonso-
Nanclares et al., 2005). Similar results for the GAD staining were obtained in FCD II cortical 
tissue, with fewer GAD positive but enlarged cells in the presence of cytomegalic neurons in 50% 
of cases (4/8). The GAD immunopositive patches was not observed in FCD I, FCD II without 
cytomegalic neurons and non-FCD tissue (Andre et al., 2008). In addition to alterations in the 
number of neurons positive for PV or calbindin, and changes in number of synaptic contacts, 
alterations of GABAA subunit composition has been studied in FCD as a possible mechanism of 
increased seizure susceptibility. Andre et al. (2008) showed that when GABA is applied to 
dissociated cytomegalic cells from FCD II the kinetics of the cells’ responses that are mostly 
mediated by GABAA are different. Zinc, which blocks GABAA receptors that lack γ2 subunits 




were less effective in cytomegalic neurons. Additionally, authors demonstrated reduced sensitivity 
(no increase in GABAA currents) to zolpidem, a type I benzodiazepine that binds with higher 
specificity to α1 subunit containing GABAA receptors in all cells sampled from FCD affected foci. 
The same group also showed in 2010 (Andre et al., 2010) that bretazenil, a partial agonist that 
increases GABA current in neurons containing α3, α4 and α5 subunits caused a larger change in 
dissociated “normal” neurons from FCD II compared to non-FCD neurons. Additionally, 
frequencies and amplitudes of sIPSCs were only increased in FCD II neurons, with larger increase 
seen in cytomegalic neurons compared to non-FCD tissue and to FCD I. Worth of note that the 
increased sIPSCs frequencies were inconsistent with Calcagnotto et al. (2005), that reported on 
decreased frequencies of sIPSCs. The authors suggested that this was due to the older patients’ 
population in the latter work. Also in the previous work comparison of sIPSCs frequencies in 
dissociated cells from mixed population of patients with different MCDs from the same group 
(Cepeda et al., 2005) did not show any statistically significant difference suggesting that grouping 
those MCDs together might obscure true pathological alterations specific to each type of lesion. 
This was evident in the latter studies comparing FCD IIb with TSC (Cepeda et al., 2012; 2010). In 
this work authors found that all neurons from FCD IIb patients possess higher GABAA mediated 
synaptic innervations compared to neurons in TSC patients. Activation of GABAB receptors by its 
agonist baclofen in FCD cortical tissue to inhibit ictal discharges was shown to have higher IC50 
compared to tissue from medial temporal lobe epilepsy patients (D'Antuono et al., 2004). White et 
al. (2001) showed that GAD65, VGAT, GABAAR α1 and α2 subunits mRNA was decreased in 
tubers compared to adjacent cortical tissue, which was further confirmed by single cell mRNA 
analysis of large dysplastic neurons and “giant” cells. GAD65 mainly was located to large 
dysplastic neurons, no immunoreactivity was detected in “giant” cells.  Additionally, increased 




mRNA levels of GABAA α4 and decreased levels of GABAA β1 were detected only in large 
dysplastic neurons. 
GABAA synaptic activity is responsible for pacemaker interictal events in the cortex (Cepeda 
et al., 2014; 2007; Avoli et al., 2005; D'Antuono et al., 2004). If the neurons innervated by this 
action potential dependent spontaneous pacemaker activity have immature properties with 
increased internal Cl- concentration, those events will become depolarizing. This may promote AP 
firing and synchronize neuronal network inducing seizures (Puskarjov et al., 2014; Talos et al., 
2012; Aronica et al., 2007). Although, the consideration of the experimental preparation causing 
physiological changes that alter the GABAA action from hyperpolarizing to depolarizing needs to 
be taken into the account (Dzhala et al., 2012) with possible utilization of perforated patch clamp 
recording technique  (Talos et al., 2012). This pacemaker activity was more frequently found (in 
34%) in patients with FCD compared to non-CD (Rasmussen Encephalitis – 12.5%, no significant 
histopathology – 16.7%) and to TSC patients (in 3%) (Cepeda et al., 2014). It was also more readily 
found in more sever FCD types (in 27% in FCD I, 34% FCD IIa/IIb, 75% FCD III associated with 
GG or DNET).  
 
ROLE OF GLUTAMATE RECEPTORS IN MCDS AND LNETS 
Several studies showed alterations in NMDA receptors subunit composition in MCDs. 
Most of them suggested a decrease in NR2A/B subunits expression in the CD affected area. 
Contradicting IHC and RT-PCR based findings in different studies still leave some questions 
unanswered.  Spreafico et al. (1998a) was the first one to show a decreased staining in superficial 
cortical layers and segregation of NR1 positive neurons in deep layers and white matter in 2 (ages 
20 and 14) out of 3 FCD patients. In the same work authors showed increased GluR2/3, an AMPA 




receptors subunits staining in “giant” dysmorphic pyramidal neurons, and increased NR1 positivity 
in “giant” dysmorphic pyramidal neurons and 50-60% of balloon cells. In previous work 
immunopositive for NR1 balloon cells were shown to be present in 30% of cases of TSC-like 
lesions (Wolf et al., 1994). Andre et al. (2004) showed that NMDA currents were increased in 
dissociated cytomegalic neurons from resected CD (not specified) tissue which is concordant with 
previous studies that showed increased positive co-staining and mRNA levels of NR1 and NR2A/B 
in cytomegalic, but also “normal” neurons from CD tissue (Finardi et al., 2013; Najm et al., 2000; 
Mikuni et al., 1999; Ying et al., 1999; Babb et al., 1998) or GG and DNETs (Aronica et al., 2001), 
and almost no mRNA and weak staining from distal parts of the same tissue. The current densities 
per unit area were decreased in this study (Andre et al., 2004), which shows that the number of 
receptors per unit area is decreased compared to non-CD cells. Subsequently they found a 
decreased Mg2+ and ifenprodil (a selective NR2B inhibitor) sensitivity of cytomegalic neurons and 
“normal” neurons from CD tissue, which with the use of RT-PCR and IHC showed a decreased 
mRNA and protein expression in a subset of cytomegalic and “normal” neurons from CD 
compared to non-CD cells. The decrease in NR2A/B expression in dendrites and soma of neurons 
was also reported in nodular heterotopia (Battaglia et al., 2002). In contrast to previous studies 
(Aronica et al., 2001; Najm et al., 2000; Ying et al., 1999) Andre et al. (2004) using RT-PCR 
showed that almost all neurons from non-CD tissue, which included epileptic tissue from either a 
cerebral infarct, temporal lobe epilepsy, trauma, or Rasmussen encephalitis, were expressing NR1 
NR2A NR2B mRNA. The authors argued that from a functional perspective it is improbable that 
native homomeric NR1 receptors exist, additionally, NR2C/D subunits which may co-assemble 
with NR1 to create a functional heteromeric NMDA receptors are minimally expressed in cerebral 
cortex. In other study by Moddel et al. (2005) authors found that ifenprodil almost completely 




suppressed epileptiform discharges in CD tissue, with no change observed in non-CD slices. This 
showed that additional processing of tissue into dissociated cells (Andre et al., 2004) may cause 
alterations in cellular membrane proteins. NR2B and NR2D mRNA was also reported to increase 
in cortical tubers from TSC patients compared to adjacent cortex. Additionally, wuthors reported 
lower IC50 of ifenprodil binding together with use-dependent I-MK801 effect, an inhibitor specific 
to NR1/NR2A and NR1/NR2B, but not to NR1/NR2C nor NR1/NR2D in tuber homogenates. At 
the same time GluR1 mRNA was decreased in tubers (White et al., 2001). Subsequent single cell 
mRNA analysis showed higher relative abundance of GluR3, GluR4, GluR6, NR2B, and NR2C 
in large dysplastic neurons than in “giant” cells or in control neurons. Whereas GluR1 and NR2A 
were lower in large dysplastic neurons. Only NR2D subunit mRNA relative abundance was higher 
in “giant” cells compared to control neurons and large dysplastic neurons. Aronica et al. (2001) 
also showed positive for NR1 balloon cells, astrocytes, oligodendrocytes and fibrillar matrix in 
GG and DNETs. Additionally, Aronica et al. (2001) showed GluR1/2 and GluR5-7 and mGluR1α, 
mGluR5 positive staining in neuronal component of GGs and DNETs. Although no astrocytes 
were stained with mGluR1α, positive staining for mGluR5 was shown in oligodendrocytes and 
some astrocytes. Those cell types were negative for mGluR5 in “normal” cortical tissue. In the 
same work mGlur2/3 were found in less than 1% of neurons in GGs and DNETs, but mainly were 
observed in astrocytes of GG and not in oligodendrocytes. The mGluR7α staining was only found 
in the granular areas within the neuropil. In the perilesional area authors showed an increased 
staining with GluR5-7, mGluR2/3 and mGluR5 in reactive, GFAP and Vimentin positive 
astrocytes compared to astrocytes from normal cortex and white matter (Aronica et al., 2001).  
Talos et al. (2008) using western blot showed an increase in GluR1 and GluR4 in tubers 
homogenates from TSC patients compared to control autopsy tissue. Using IHC authors showed 




that GluR1 increase was observed in “normal” pyramidal and dysplastic neurons but low in most 
“giant” cells, dysplastic astroglia and reactive astrocytes. In contrast GluR4 was increased in 
“giant” cells, astroglia, and reactive astrocytes but low in “normal” pyramidal and dysplastic 
neurons. Western blot for GluR2 and GluR3 showed lower levels in cortical tubers than in control 
tissue and cell specific IHC showed that it was abundantly expressed in “normal” pyramidal 
neurons but low in most dysplastic neurons, “giant” cells, dysplastic astroglia and reactive 
astrocytes. NR1 subunit levels and expression was not different between tubers and controls. 
Western blot showed no significant difference in NR2A between tubers homogenates and control 
ones, but with IHC authors saw high expression in “normal” pyramidal neurons, whereas it was 
low or absent in most dysplastic neurons and giant cells. Dysplastic astroglia and reactive 
astrocytes both expressed high NR2A levels. Total expression of NR2B and NR3A was 
significantly greater in cortical tubers relative to controls, with IHC NR2B expression was high in 
most “normal” and dysplastic pyramidal neurons, while it was low in “giant” cells dysplastic 
astroglia and reactive astrocytes. The NR2C subunit expression was low in “normal”, dysplastic 
pyramidal neurons and “giant” cells, but was high in most of the dysplastic astroglia and reactive 
astrocytes. The NR2D subunit expression was high in “giant” cells but was low or undetectable in 
other cell types. The NR3A subunit expression was high in all tuber cell types.    
In summary, the different malformations may have different post-synaptic receptors 
affected in different malformed component. Increased GABAergic innervation that was observed 
in sever FCD cases (FCD I < IIa, IIb, < III), and in GG and decreased in TSC. NMDA receptors 
increase in normal components in TSCs but decreased in malformed components and in tubers. 
AMPA receptors immunoreactivity displayed similar to NMDA immunoreactivity distribution, 
and metabotropic glutamate receptors expression was also altered. Additionally, subunit 




composition of the tested GABAergic, NMDA, AMPA, and mGluR post-synaptic receptors are 
altered not only in neuronal components but also in astrocytes. 
1.7 NON-NEURONAL NETWORK HYPEREXCITABILITY 
MECHANISMS IN MCDS AND LNETS  
Multiple studies on FCD II, TSC, GG and DNETs have reported on astrogliosis with 
increased expression of GFAP, a marker for reactive astrocytes, and microgliosis with Human 
Leukocyte Antigen -  antigen D Related (HLA-DR), marker for activated microglia in the grey 
matter and one of the major histocompatibility complex (MHC) class II receptors. Additionally, 
those studies have shown increased expression of classical complement pathway components – 
C1q, C3c, C3d in astrocytes, glia and neurons. (Sun et al., 2016; Zhang et al., 2016; 2015; Aronica 
and Crino, 2011; Aronica et al., 2008b; 2005; 2001; Boer et al., 2010a; 2008; 2006; Iyer et al., 
2010; Sosunov et al., 2008). Differences in the levels of activated microglia and astrocytes between 
FCD I, FCD II without difference in seizure frequency and duration (Iyer et al., 2010) suggest that 
this is not a simple result of seizure activity. Activation of mTOR pathway in FCD II but not FCD 
I may be a possible contributing factor to inflammatory process. 
 
ASTROCYTES – NORMAL PHYSIOLOGICAL FUNCTION 
Embryonic astrocytes derive from neuroepithelial radial glia neuronal progenitors and 
intermediate progenitors of the subventricular zone (SVZ) later in corticogenesis – around E15-
E18 in mice (Siddiqi et al., 2014; Levison and Goldman, 1993). Second wave of astrogenesis 
happens latter at the postnatal stages from local differentiated astrocytes of a gray matter at P0-
P21 (Ge et al., 2012). Astrocytes are diverse population of cells with brain region variable density 
and differential functions (Chai et al., 2017; Khakh and Sofroniew, 2015; Tsai et al., 2012).  There 




are two generally recognized classes of astrocytes in cortex – fibrous, with straight and long 
processes that mostly populate white matter and express high levels of GFAP. The second class 
are protoplasmic astrocytes that possess highly branched bushy processes, populate gray matter 
and in the healthy cortex do not express high levels of GFAP (Tabata, 2015). However, this 
classification may underestimate the number of different astrocytes types (Zhang and Barres, 
2010).There are characteristic differences in astrocytes classes and organization between humans 
and mice. For instance, some classes of astrocytes are found only in primates like interlaminar 
astrocytes that populate layer I and astrocytes in layers 5 and 6 with long varicose fibers. 
(Oberheim et al., 2009).   
Due to inability to generate action potentials in undamaged tissue (O'Connor et al., 1998; 
Bordey and Sontheimer, 1998; Verkhratsky and Steinhauser, 2000) astrocytes have long been 
considered as a passive participants in central nervous system homeostasis (Ben Haim and 
Rowitch, 2017; Sontheimer et al., 1994). Their few of many passive functions include K+ ions 
balance maintenance through the uptake by Na+/K+-ATPase, Na+/K+/2Cl- contrasporter, and 
spatial buffering, mainly, through inwardly rectifying Kir4.1 channels. The Kir4.1 is, evidently, 
coupled to water balance homeostasis through  perivascular and subpial membrane anchored 
AQP4 channels (Devinsky et al., 2013; Amiry-Moghaddam et al., 2003; Simard and Nedergaard, 
2004), with the subsequent K+ ions redistribution to the syncytium through coupled gap junctions 
formed by connexin hemichannels Cx43, Cx30 and Cx26 (Nagy and Rash, 2003; Steinhauser and 
Seifert, 2012). Additional passive roles include glutamate clearance from extracellular 
environment mostly through EAAT1 (GLAST-1 in rodents) and EAAT2 (GLT-1 in rodents) 
transporters (Malarkey and Parpura, 2008; Heja, 2014). Oxygen, glucose and its metabolites 
redistribution and delivery through gap junctions for synaptic transmission maintenance (Rouach 




et al., 2008; Kowianski et al., 2013). Stimulation of axonal growth and regeneration, 
synaptogenesis, regulation of local blood flow (Smith et al., 1986; Ullian et al., 2001; Kowianski 
et al., 2013). Last two decades were flushed with an extensive research of astrocytic active 
functions. Discovery of Ca2+ dependent glutamate release by astrocytes in cultures (Parpura et al., 
1994) that evidently affects extrasynaptic NMDA receptors (Araque et al., 1998), which latter was 
corroborated by Bezzi et al.(1998) in acute hippocampal slice preparation, led to the concept of 
“tripartite synapse” (Araque et al., 1999b; Araque et al., 1999a; Perea et al., 2009). In addition to 
glutamate astrocytes are capable of a vesicular release of D-serine, adenosine,  ATP, GABA, TNFα 
(Panatier et al., 2006; Martineau et al., 2008; Henneberger et al., 2010; Pascual et al., 2005; Martin 
et al., 2007; Zhang et al., 2003; Butt, 2011; Kozlov et al., 2006; Stellwagen and Malenka, 2006; 
Beattie et al., 2002; Kowianski et al., 2013); and slower lysosomal release of ATP (Li et al., 2008a; 
Jaiswal et al., 2007; Zhang et al., 2007). Although the debate on vesicular release is still ongoing 
(Sloan and Barres, 2014; Devinsky et al., 2013).  
Alternative release mechanisms - including reversal of glutamate transporters, unpaired 
connexin/pannexin hemichannels on the cell surface, pore-forming P2X7 receptors and swelling-
induced activation of volume-regulated anion channels, have also been investigated (Malarkey and 
Parpura, 2008). These multiple functions of astrocytes in different processes might be altered in 
pathophysiological states like epilepsy (Binder and Steinhauser, 2006).  
In response to injury and infection or tissue degeneration and cell death seen in degenerative 
disorders and epilepsy astrocytes can increase their proliferation, alter their morphology, molecular 
machinery, function and gene expression, with increased expression of GFAP and Vimentin 
serving as a marker of these changes. The changes that happens in reactive astrocytes are 
dependent upon the nature and the severity of the insult (Sofroniew, 2009).  




ASTROCYTES ACTIVATION IN MCDS AND LNETS 
Astrogliosis in TSC patients was described to have similar morphological and 
immunophenotypical characteristics as HS with MTLE patients. The immunoreactivity to anti-
GFAP, anti-CD44 and anti-S100β Ab, proteins that are expressed in white matter fibrous type 
astrocytes was increased in both TSC and HS MTLE tissue compared to perituberal and non-
sclerotic hippocampal tissue. The significant decrease in immunoreactivity to anti-EAAT1 and 
anti-EAAT2 – glutamate transporters, anti-Glutamine Synthetase that transforms glutamate to 
glutamine, and anti-Kir4.1, an inward rectifying potassium channel, proteins that are expressed in 
protoplasmic grey matter astrocytes was evident in both TSC and HS MTLE tissue. Lucifer Yellow 
filled astrocytes in TSC and HS MTLE tissue also demonstrated a similar morphology. In contrast 
to HS there was a second population of patches of Vimentin and Nestin positive astrocytes that 
were surrounding giant cells in tubers. Additionally, there was an increased staining in astrocytes 
in tubers for superoxide dismutase (Mn-SOD), a mitochondrial enzyme, compared to HS MTLE 
tissue (Sosunov et al., 2008). Boer et al. (2008) showed increased immunoreactivity to C1q, C3c 
and C3d in astrocytes of TSC resected cortical tubers compared to autopsy controls. Additional 
activation of inflammatory cascades may be through HMGB1, a chromatin component that is 
released by injured cells and controls transcription of different genes including proinflammatory. 
Upon secretion it can bind receptor for advanced glycation end products (RAGE), TLR2 and 
TLR4. Binding of HMGB1 to TLR4 plays a role in generation and sustenance of seizures through 
tyrosine phosphorylation of NMDA receptor NR2B subunit in MTLE (Maroso et al., 2010). Zurolo 
et al. (2011) using qRT-PCR, in-situ hybridization and IHC showed increased TLR4 receptor and 
transcription factor, and RAGE in FCD, TSC and GG cases in astrocytes (GFAP positive cells), 
dysplastic neurons, but only occasional staining in balloon and giant cells. Occasional TLR2 was 




seen in astrocytes as well.  The HMGB1 mRNA was not significantly increased as tested by qRT-
PCR, however increased immunoreactivity was observed in all cells of dysplastic FCD, TSC tubers 
and GG tumors, with additional cytoplasmic staining in glial cells. Control autopsy and 
peritumoral tissue had similar expression profiles of HMGB1, which were lower than the 
dysplastic/tumor/tuber tissue. This pathway was investigated in an additional study of fetal TSC 
resected tissue by Prabowo et al. (2013) that showed increased TLR2, TLR4 and RAGE 
immunoreactivity in giant cells, that were also positive for GFAP, vimentin and nestin and 
mTORC1 activation markers (pS6, pS6K, p4EBP1). 
Murine model of astrocyte specific conditional deletion of TSC1 (exons 17 and 18) driven by 
GFAP-Cre expression showed increased astrogliosis and, after the first month of age displayed 
electrographic seizures (Wong et al., 2003; Uhlmann et al., 2002). The same CKO mice species 
were used by Zhang et al. (2015) to show increased mRNA and protein levels of IL-1β, CCL2 and 
CXCL10 with qRT-PCR and IHC in neocortex and hippocampus and was reflected in astrocytic 
cultures, which was reversed by treatment with mTORC1 inhibitor rapamycin. Using IHC authors 
showed that IL-1β colocalize with GFAP positive astrocytes in brain slices of four-week-old 
TSCGFAP CKO mice. Using Western blot for CXCL10 authors show that the protein levels were 
increased in four-week-old TSCGFAP CKO mice compared to control mice, similar results were 
obtained in astrocytic cultures, and rapamycin and epicatechin-3-galate treatment decreased its 
levels either in-vivo or in astrocytic cultures in-vitro. Importantly the increased expression of 
cytokines was observed before the onset of seizures. Blocking IL-1β and CXCL10 with 
epicatechin-3-galate at least partially reversed the elevated levels of cytokines and chemokines, 
reduced seizure frequency and prolonged survival of TSCGFAP KO mice. These early changes were 
presumed to be a result of innate immune system in the brain and not infiltration of peripheral 




macrophages. Another murine model of epilepsy with the predominant in the brain β1-integrin 
transmembrane receptor subunit conditional knockout in radial glia, the protein that is required for 
astrocytes acquisition of non-reactive state (Robel et al., 2015; Robel et al., 2009), showed 
increased excitability as evident by spontaneous seizures during the first six postnatal week. This 
was complemented by whole-cell patch-clamp recording in acute slices from single pyramidal 
neurons in layers 2/3 that showed depolarized RMP, increased input resistance Rin, shorter latency 
to interictal and ictal events in Mg2+ free media, and increased AP firing in response to depolarizing 
current steps compared to control cells. This was correlated with increased protein levels of 
NKCC1 at six weeks of age and decreased protein levels of KCC2 at six months of age as shown 
with Western blot assay and redistribution of KCC2 to perisomatic region as evident with IHC. 
Importantly, there was no cytoarchitectural changes and neuronal specific deletion of β1-inegrin 
did not induce hyperexcitability.  (Robel et al., 2015). Astrocytes can be a source of local glutamate 
dependent interictal paroxysmal depolarization shifts that cause neuronal synchronized burst firing 
(Tian et al., 2005).  
Intrinsic molecular mechanisms responsible for astrogliosis may be regulated by the local 
environment (Schipke et al., 2008). Interestingly, astrocytes proliferation is partially controlled by 
MAPK pathway (Tien et al., 2012), with BRAFV600E expression at physiological levels 
contributing to increased proliferation in spinal cord. Conditional deletion of BRAF exon 12 
containing the kinase domain in radial glia caused a decrease in astrocytes proliferation, as evident 
by dividing cells DNA incorporation of 5-Ethynyl-2’-deoxyUridine (EdU) in astrocytes. The 
contribution of MAPK pathway activation to gliogenesis in spinal cord was confirmed in cortex 
through manipulation of MEK1/2 in NestinCre and hGFAPCre mouse lines, also shown with 




introduction of mutated RAS BRAF (V600E) and MEK1/2 in Neurog2 and Ascl1 mouse lines (Li 
et al., 2014; Li et al., 2012). 
 
MICROGLIA – NORMAL PHYSIOLOGICAL FUNCTION 
Microglia are the primary immune and cytokine-producing cells of CNS. Microglia possess a 
wide variety of shapes from ramified with extending processes to amoeboid macrophage-like 
shape and it can change from one shape to another depending on the environmental signals , with 
current view of amoeboid shape as an activated form and ramified as a silent form, although both 
forms may perform different functions. (Lloyd et al., 2017; Salter and Stevens, 2017; Werneburg 
et al., 2017; Masuda and Prinz, 2016; Miyamoto et al., 2016; Wake et al., 2013; Kreutzberg, 1996).  
Derived from yolk sack myeloid progenitors microglia start to populate CNS at E9 through 
E14.5 and with the second wave between E14-E16 in mice and at gestational week 4.5 and 12-13 
in humans (Reemst et al., 2016; Matcovitch-Natan et al., 2016; Ginhoux et al., 2010; Verney et 
al., 2010; Monier et al., 2007). In CNS microglia have been shown to participate in such diverse 
array of processes as subpalial dopaminergic neurons axonal tract formation, DAP12 (Kiialainen 
et al., 2005; Lanier and Bakker, 2000), a transmembrane adaptor protein, and Cx3cr1 fractalkine 
receptor (Liu et al., 2009; Harrison et al., 1998) dependent Lhx6 and PV positive fast-spiking 
interneuron migration (Squarzoni et al., 2014). Microglia was also shown to participate in DAP12 
and Cx3cr1 dependent neurite-growth and corpus collosum formation (Pont-Lezica et al., 2014), 
and in Ca2+ dependent and actin filament mediated synaptogenesis (Miyamoto et al., 2016). 
Paolicelli et al. (2011) showed that microglia also participate in synaptic pruning partially through 
Cx3Cr1 fractalkine receptor, although the pruning may be delayed in that case due to decreased 
microglia cell densities in CNS. Stevens et al (2007) showed that microglia participate in synaptic 




pruning through a complement pathway component C1q and C3 upregulation. Paolicelli et al. 
(2011) also showed microglia involvement in synaptic maturation. Riazi et al. (2015) showed that 
microglia affect basal synaptic transmission, and functional synapse plasticity. Other studies  
(Bessis et al., 2007; Rakic and Zecevic, 2000) showed microglia participation in promotion of 
programmed cell death and designated neurons phagocytosis. Ziv et al. (2006) showed microglia 
participation in maintenance of neurogenesis. Nimmerjanh et al. (2005) showed that microglia, 
through their dynamic ramified processes participate in immune surveillance response to injury. 
Microglia also participate in immunological signaling (Salter and Stevens, 2017; Aloisi, 2001).  
 
MICROGLIA ACTIVATION IN MCDS AND LNETS 
Sun et al. (2016) showed that in FCD IIb and TSC resected brain tissue there is a decrease in 
mRNA and protein levels of CD47, its receptor SIRPα and CD200, but not its receptor CD200R 
that is mainly expressed by microglia. CD47/SIRPα (Gitik et al., 2011; Oldenborg et al., 2001) 
and CD200/CD200R (Hoek et al., 2000; Wright et al., 2000) exert inhibitory effects on microglia 
phagocytosis, hence authors hypothesized that in malformed components of FCD IIb and TSC 
(dysmorphic neurons, balloon cells and giant cells) these molecules levels would be decreased 
compared to autopsy controls hence dis-inhibiting microglia. This decrease was shown by IHC. 
Increased expression of IL-1β in microglia and neurons was found in FCD, GG and DNET 
(Ravizza et al., 2006). Aronica et al. (2005) showed increased HLA-DR immunoreactive microglia 
in GG and DNETs with some clustering around neurons compared to control autopsy and 
peritumoral area. The increase of HLA-DR was higher in peritumoral area compared to the autopsy 
control. The increase in HLA-DR positive microglia correlated with the duration of epilepsy and 
the preoperative seizure frequency. Iyer et al. (2010) showed increased HLA-DR immunoreactive 




microglia in FCD II dysplastic area compared to autopsy cases with viral encephalitis and multiple 
sclerosis and FCD I. While HLA-DR immunoreactive microglia numbers were not significantly 
different between FCD I and epilepsy control cases. In TSC resected brain tubers Sosunov et al. 
(2008) did not observe a widespread activation of microglia using HLA-DR antibody staining. On 
the other hand, Boer et al. (2008) reported on increased HLA-DR positive microglia in TSC 
resected brain tubers compared to autopsy controls and perituberal tissue. Those HLA-DR positive 
microglia were clustered around dysplastic neurons, blood vessels, and balloon cells. The authors 
also showed that number of HLA-DR positive microglia was correlated with the preoperative 
frequency of seizures. Additionally, the C1q, C3c and C3d a part of a complement system was 
observed in microglia, astrocytes, neurons and giant cells of resected tubers. The IL-1β and its 
receptor IL-1RI showed similar pattern of immunoreactivity to the complement system. In the 
previous work on FCD II resected tissue Boer et al. (2006) demonstrated similar to TSC increase 
of HLA-DR positive microglia in dysplastic tissue compared to autopsy control and correlation 
with preoperative seizure frequency and duration of epilepsy. Zurolo et al. (2011) using qRT-PCR 
in-situ hybridization and IHC showed increased expression of TLR2 and RAGE in microglia 
(HLA-DR positive), balloon, and giant cells, with only occasional immunoreactivity to TLR4 in 
FCD, TSC and GG resected tissue compared to autopsy controls. HMGB1 was evident in 
cytoplasm of microglia compared to nuclear localization in neuronal component in FCD dysplastic 
tissue, TSC tubers, and GG tumors. 
Using murine model of TSCGFAP conditional knockout Zhang et al. (2016) showed increased 
numbers of iba1 positive microglia. The increase in iba1 positive microglia correlated with the 
earliest age of seizure onset. These microglia cells were larger than their counterparts in control 
mice. They also showed that inhibition of microglia activation with minocycline (Yrjanheikki et 




al., 1998), an anti-inflammatory broad spectrum tetracycline antibiotic,  prevented the increase in 
iba1 positive microglia and the increase in cell size but did not affect astrogliosis (increased 
number of cells positive for GFAP), and cytokine/chemokine (IL-1β, CCL2, CXCL10) production 
as evident by qRT-PCR and Western blot, and did not have a significant effect on seizures 
progression and survival. However, there was a trend towards less frequent seizures. The effects 
of minocycline did diminish by 7 weeks of mice age, and the higher doses caused premature death 
probably associated with liver toxicity (Zhang et al., 2016).  
Increased inflammatory reaction in CNS causes morphological and molecular changes in 
microglia, increases proliferation and size that can increase neuronal excitability through a direct 














CHAPTER 2 RESEARCH OBJECTIVES AND APPROACH 
Recent discovery of BRAFV600E activating somatic mutation in 30-50% of LNETs 
(Barkovich et al., 2015; Blumcke et al., 2014; Koelsche et al., 2013; Schindler et al., 2011), which 
has been extensively described in solid non-brain tumors (Mikhailenko et al., 2017; Taieb et al., 
2016; Singh et al., 2015; Chaft et al., 2012; Janku et al., 2011) allows to develop and study a new, 
etiologically accurate animal models of drug refractory epilepsy associated with LNETs. 
Application of Immunohistochemical markers that has been highly associated with LNETs, 
examination of synaptic network activity and ion channels together with single-cell ex-vivo 
electrophysiology, electro-corticographic recordings (ECoG) and RNA-sequencing allowed 
elucidation of pathogenic mechanisms that caused neuronal hyperexcitability. Based on recent data 
we tested the overall hypothesis that constitutive activation of RAS-RAF-ERK and/or mTOR 
pathway alters neuronal and synaptic excitability as well as cytoarchitectural cortical 
organization thus shifting cortical networks to seizure prone states. We hypothesized that 
constitutive BRAF activation directly cause definable changes in neuronal conductance and 
synaptic mechanisms by pathway overactivation, and that these can be rescued by 
experimentally downregulation or upregulation of the affected mechanisms. 
The goals of the current work were: 
Goal 1. To determine whether BRAFV600E mutation and increased copy number variant of 
its wild type – BRAFwt alter neocortical glial and/or neuronal morphology and cortical 
cytoarchitecture and whether those alterations correlate with increased inflammatory 
reaction.  
I used a newly developed LNETs model in our lab in which introduction of human 
BRAFV600E mutations or BRAFwt into glial and neuronal progenitors is accomplished by 




piggyBac-mediated transposition and in-utero electroporation. We used two promoters-
helpers/donors plasmids driven systems, Glast-PB and Nestin-PB, to test whether cortical 
cytoarchitecture alterations dependent on the population of progenitor cells affected by 
BRAFV600E expression. Immunohistochemistry was used for GFAP and iba1 markers that are 
increased in LNETs and in FCD (Aronica and Crino, 2011; Aronica et al., 2008b; Aronica et al., 
2005; Boer et al., 2006) to assess changes in reactive gliosis and activation of microglia. 
Goal 2. To Identify the alteration in transcriptome profiles of BRAFV600E expressing 
animals 
 RNA-sequencing was performed to examine alterations of tissue-wide gene expression in the 
transfected, EGFP positive, cortical patches from three experimental conditions, Glast+ 
BRAFV600E, Glast+ BRAFwt, Glast+ control-FP (EGFP only electroporated). Isolation of whole 
RNA from transfected, mostly containing somatosensory cortexes were done using ambion RNA 
recovery kit. We used Illumina NextSeq-500 library preparation, together with HISAT2 to map 
the sequences to mouse genome (Pertea et al., 2016), Stringtie to quantify gene abundance (Pertea 
et al., 2015) and DESeq2 to explore differentially expressed genes (Love et al., 2014). 
Goal 3. To determine whether constitutively active BRAFV600E and/or BRAFwt alter 
electrophysiology of Neocortical Pyramidal Neurons.  
Whole-cell patch clamp recordings were used to assess the changes in neuronal excitability. I 
tested the hypotheses that constitutive activation of BRAF in dysplastic neurons can result in 
depolarization of resting membrane potential, hyperpolarized AP voltage threshold, lower 
rheobase (current threshold), increased number of APs fired to given current step (Input-Output), 
increased hyperpolarization activated current (Ih), increased calcium current (ICaT, ICaL); or 
decreased potassium currents (IKA, IKDr, IKs). Examination of changes in those mechanisms have 




shown how the excitability in the affected neurons is increased. Additionally, I tested the 
hypothesis of decreasing the increased excitability by activating the voltage gated 
tetraethylammonium sensitive sustained potassium conductances.  
 To test alteration in synaptic properties of BRAFV600E expressing neurons and whether  there 
were  alterations in the presynaptic release machinery, and post-synaptic responses I performed 
whole-cell patch-clamp recording of action potential dependent spontaneous post-synaptic 
currents (sPSCs), and action potential independent miniature PSCs and examined the frequencies 
and amplitudes of those events. 
To test whether those neuronal specific changes are sufficient to cause seizures I used 
depolarizing channelrhodopsin cation channel (pCAG-ChR2) (Lin, 2011) responsive to blue light 
that was electroporated together with pPB-BRAFV600E and pGlast-PB at E14.5-E15.5 embryonic 
stages in mice and after they reached adolescence performed ex-vivo whole-cell patch-clamp 
together with ChR2 stimulation to test for seizure generation threshold. Electrocorticographic 
(ECoG) recordings were performed to test whether BRAFV600E transfected mice do have 
spontaneous seizures in-vivo. Additionally, I tested whether acute inhibition of BRAFV600E with 
currently available inhibitor Vemurafenib/Zelboraf (PLX4032, PLX4720) prevents neuronal 
hyperexcitability in ex-vivo cortical slices. 
The overall results from these experiments provided insights into intrinsic neuronal 
excitability mechanisms that may be involved in epileptic seizures generation in RAS-RAF-ERK 
and/or mTOR related LNETs. Additionally, RNA sequencing provided insights on tissue specific 
non-cell autonomous alterations related to expression of BRAFV600E, which may be compared 
to the previously published results from resected brain tissue of patients with GG, DNETs, FCD, 




and TSC (Zhang et al., 2013; Boer et al., 2010a; Aronica et al., 2008a; Hoischen et al., 2008; 















CHAPTER 3 RESULTS 
GOAL-1 CYTOARCHITECTURAL AND MORPHOLOGICAL 
ALTERATIONS IN MURINE CORTEX OF BRAFV600E TRANSFECTED 
ANIMALS. 
 Expression of BRAFV600E in Glast+ and Nestin+ neuroglial progenitors induced with 
In-Utero Electroporation in mice increased gliogenesis and decreased the percentage of mature 
differentiated neurons in Glast+ condition, and increased neurogenesis and decreased astrocytes 
percentage in Nestin+ condition (Figure 3C,3E,3F). In Glast+ BRAFV600E cortical slices 
increased number of neurons remaining in lower cortical layers was observed (Figure 3C). 
Balloon-like cells with round shape and increased cytoplasm to nucleus ratio were found in both 
Glast+ and Nestin+ BRAFV600E cortical slices, starting at P30 aggregates of those cells were also 
observed (Figure 3B,3D,3G). Some of the balloon-like cells were immunoreactive to both upper 
and lower cortical layer markers, Cux1 and Ctip2, some were positive for astroglial marker GFAP, 
but not for neuronal marker NeuN (Figure 3D). In Nestin+ BRAFV600E cortical slices soma size 
of the EGFP positive cells located in the vicinity of the ventricle was larger than neurons in layer 
2/3 (Figure 4). The immunoreactivity to microglia and reactive astrogliosis markers - Iba1, GFAP 
was increased in BRAFV600E slices (Figure 5 - Increased activation of astrocytes in BRAFV600E transfected 













Figure 3 - Dysmorphogenesis, migrational delay, astrogenesis and neurogenesis in 
BRAFV600E brains. 
 





Figure 3. BRAFV600E expression in neuroglial progenitors at embryonic ages E14-E15 causes neuron 
migrational delay and cellular dysmorphogenesis. A. In-Utero Electroporation (IUE) experimental design. B. 
Representative image of Glast+ BRAFV600E electroporated mouse brain slice at post-natal day 180 showing 
aggregates of balloon-like cells near the pia and aggregates of a crescent shaped cells in layers 4 and 5. C. Cux1, 
an upper cortical layer marker and Ctip2, a lower cortical layer marker shows that most of the Glast+ 
BRAFV600E transfected neurons reach appropriate cortical layers relative to embryonic age at IUE. Insets show 
zoomed in neurons positive for Cux1, and negative for Ctip2 in upper layer 2. Lower panel shows 3 neurons 
located in the lower cortial layers and positive for cux1. D. Balloon-like cells and aggregates (panels I and II, 
Roman numerals – R.n.) of balloon-like cells found in Glast+ BRAFV600E transfected brains. Panels 
II,IV,VI,VIII (even R.n.) show anti-HA stain confirmation of pPB-BRAFV600E presence. Panels III-IX with odd 
R.n. show balloon-like cell stained positive for both Cux1 and Ctip2. Panels XI-XVII, odd R.n. show a balloon-
like cell stained positive for Glial Fibrilary Acidic Protein (GFAP) an astrogllial markers. Panels XII-XVII, even 
R.n. show a ballon-like cell negative for NeuN, a neuronal marker. Panels XIX-XXI showing coronal section 
from Nestin+ BRAFV600E with balloon-like cells aggregates in a piriform cortex area (white arrowhead). E. 
Gross neuron counts (left panel) and scaled to max neuron counts (right panel) - distance to pia measurement 
shows that there is a decrease in EGFP positive neuronal content in Glast+ BRAFV600E transfected mouse 
cortical slices and that higher number of the BRAFV600E transfected EGFP positive neurons targeted for upper 
cortical layers under both Glast+ and Nestin+ do not reach their deisgnated location compared to Glast+ control-
FP transfected brain slices (p<0.001), and to Glast+ BRAFwt transfected brain slices (p<0.001), there was also 
higher number of Glast+ BRAFwt transfected neurons that did not reach designated cortical layers compared to 
Glast+ control-FP (p<0.001); significant difference in neuronal distance to pia was also present between Glast+ 
BRAFV600E and Nestin+ BRAFV600E (p=0.001)  Due to non-homogenous variance - Levene test (3, 28606) = 
1674.918, p<0.0001, Welch test with Games-Howell post-hoc correction were used (3, 9803.913) = 970.974, 
p<0.001. The results were confirmed with cumulative distribution nonparametric Mann-Whitney U test – Glast+ 
BRAFV600E to Glast+ control-FP, U= 31122376, p<0.001; Glast+ BRAFV600E to Glast+ BRAFwt, U= 
18003030, p<0.001; Glast+ BRAFwt to Glast+ control-FP, U= 26624785, p<0.001; Nestin+ BRAFV600E to 
Glast+ control-FP U= 11954144.5, p<0.001; Nestin+ BRAFV600E to Glast+ BRAFwt, U= 7186563, p<0.001; 
Nestin+ BRAFV600E to Glast+ BRAFV600E, U= 12109290.5, p<0.001. F. Neuron to astrocytes percent ratio 
showing increased astrogliosis (EGFP positive cells) in BRAFV600E electroporated murine cortical slices. Due 
to non-homogenous variance (Levene test (3, 243) =4.574 and 4.575 for neurons and astrocytes respectively 
p=0.004), Welch test F(3, 106.49)=183.71, p<0.001 with Games-Howell posthoc correction was used for 
statistical comparison. Astrocytes percentage was increased in Glast+ BRAFV600E electroporated slices (n=44 
slices, 8 brains) compared to Glast+ control-FP only (n=43 slices, 7 brains p<0.001); and compared to Glast+ 
BRAFwt electroporated slices (n=18 slices, 5 brains p<0.001). And neuronal percentage was decreased in Glast+ 
BRAFV600E electroporated slices compared to Glast+ control-FP (p<0.001); and compared to Glast+ BRAFwt 
electroporated slices (p<0.001); but not in Glast+ BRAFwt electroporated slices compared to Glast+ control-FP 
electroporated slices for both astrocytes and neurons percentage (p=0.996). Astrocytes percentage was decreased 
in Nestin+ BRAFV600E (n=20 slices, 3 brains) compared to Glast+ BRAFwt (p<0.001); to Glast+ control-FP 
(p<0.001); to Glast+ BRAFV600E (p<0.001). Neuronal percentage was increased in Nestin+ BRAFV600E 
compared to Glast+ BRAFwt (p<0.001); to Glast+ control-FP (p<0.001); and to Glast+ BRAFV600E (p<0.001). 
G. Frequency of slices with balloon-like cells and balloon-like cells aggregates in Glast+ BRAFV600E 
transfected brains according to the post-natal age. Each bar represent one brain. Scale bars for B. - 500 µm; C. - 
500 µm and 50 µm zoomed in images, Lower panel – 100 µm for the wide field view, 50 µm for single neurons, 
10 µm for single zoomed in neuron; for D. I,X – 50 µm; II-IX, and XI-XVIII, R.n. – 20 µm; for F. 1 mm. * - 
p<0.05, ** - p<0.01, *** - p<0.001. Error bars are ±2SEM. 
 





Figure 4 - Nestin+ BRAFV600E large cells remained closer to the lateral ventricle  
 
 
 Astrocytes immunoreactivity to characteristic astrocytic markers - ALDH1L1, S100β was not 




Figure 4. BRAFV600E expression in Nestin+ neuroglial progenitors. A.Representative image of EGFP positive 
cells in subventricular area compared to cells in layer 2/3 of somatosensory cortex that are quantified in B. Area 
measured in Nestin+ BRAFV600E EGFP positive cells in A in the upper panel, and diameter of those cells in the 
lower panel showing increased size of subventricular located cells (n=17) compared to layer 2/3 neurons (n=11, 
paired sample T=7.883, p<0.001 for area and T=8.224, p<0.001 for diameter) . Scale bars for A – 500 µm * - 
p<0.05,** - p<0.01, *** - p<0.0001. Error bars are ±2SEM. 
 








Figure 5. BRAFV600E transgene in Glast+ neuroglial progenitors increases gliogenesis and induce reactive 
astrogliosis. A. Whole-slice image showing increased GFAP immunoreativity in somatosensory cortex 
transfected with Glast+ BRAFV600E compared to Glast+ control-FP and to Glast+ BRAFwt transfected 
brains(upper 3 panels). Whole-slice image showing increased GFAP immunoreactivity in more frontal part of 
somatosensory cortex transfected with Nestin+ BRAFV600E (lower panel). B. GFAP positive cells were also 
immunopositive to astrocytes marker ALDH1L1(white arrowheads). Scale bars for A(upper panel) 1 
mm;(lower panel) 500 µm. B.- 50 µm; * - p<0.05,** - p<0.01, *** - p<0.0001. Error bars are ±2SEM. 
 




GOAL-2 RNA SEQUENCING OF TRANSFECTED WITH GLAST+ 
BRAFV600E, BRAFWT, CONTROL-FP BRAINS TISSUE. 
In order to determine whether the increased immunoreactivity to GFAP and Iba1 observed was 
due to reactive gliosis and potential inflammatory responses in the regions of mutation bearing 
cells, I performed an RNA-sequencing experiment to compare the gene expression profiles of 
patches of cortex containing BRAFV600E, BRAFwt, or EGFP only transgenes in Glast+ 
condition. Previous studies have shown that approximately 5-10% of cells are transfected with 
IUE (Figueres-Onate et al., 2015; Rice et al., 2010), and so the majority of any change in transcripts 
is likely driven by changes in gene expression profiles in untransfected reacting cells in those 
patches. Using an unsupervised hierarchical clustering analysis of all genes in 12 samples, 4 in 
each transgene condition, I found that BRAFV600E, control-FP, and BRAFwt conditions clustered 
separately (Figure 6A). Differential expression and gene ontology analysis indicated a significant 
increase in the expression of genes in the inflammatory immune response pathway (H2-Aa, CD74, 
H2-Ab1, CD48, CD109, Cxcl16, Ccr1), and classic complement pathway components (C3, 
Serpinf1, C4b, C1s1, C1ra, Serpina3i, Serpina3b, Serpina3n) (Figure 6D, 6G; Table 1). Iba1 and 
CD74 (HLA-DR), two markers of microglia activation were also increased in Glast+ BRAFV600E 
condition compared to control-FP (Figure 6G), it was also increased compared to BRAFwt at 
p=0.011 for Iba1 and p=0.007 for CD74. Similarly, markers of astrocyte activation, GFAP and 
Vimentin, were also significantly upregulated in the RNA-seq profiles of the four BRAFV600E 
samples relative to the other transgene conditions. Overall, the pattern of gene expression changes 
in cortical tissue containing a subpopulation of cells expressing BRAFV600E is consistent with 
these cells causing a glial activation and neuroinflammatory response (Figure 6B, F, G).  




Interestingly, the decreased expression of potassium channels (Table 2) is consistent with previous 


























Figure 6 - RNA sequencing of Glast+ BRAFV600E shows inflammation and activation 
of complement cascade 
 









Figure 6. Unsupervised Hierarchical Clustering Analysis of Glast+ BRAFV600E, Glast+ 
control-FP and Glast+ BRAFwt tissue-wide expression profile. A. Four clusters of three 
conditions with four replicates each (Lamarre et al., 2018), Glast+ BRAFV600E, Glast+ 
control-FP, Glast+ BRAFwt, 17,037 genes with at least one of 12 replicates having TPM >=1 
were used. B. Expression vallues in transcripts per million (TPM) of GFAP and vimentin in 
three conditions; GFAP is increased in BRAFV600E (20.78 fold increase, p=0.000197, 
FDR=0.014) and BRAFwt (7.99 fold increase, p=0.0166, FDR=0.32) compared to control-
FP; BRAFV600E  to BRAFwt (2.67 fold increase p=0.03066, FDR=0.185); vimentin was 
also increased in BRAFV600E compared to control-FP (11.07 fold increase p=0.0000804, 
FDR=0.014) and to BRAFwt (3.63 fold increase p=0.00421692, FDR=0.131); BRAFwt to 
control-FP (3.13 fold increase p=0.025, FDR=0.35); while GAPDH was insignificantly 
changed, BRAFV600E to control-FP (1.10 fold decrease p=0.025, FDR=0.175), to BRAFwt 
(1.03 fold decrease p=0.52, FDR=0.718); BRAFwt to control-FP (1.13 fold decrease p=0.31, 
FDR=0.7). C. Represantative astrocytes in BRAFwt immunoreactive to ALDH1L1 and 
GFAP. Lower panel zoomed in astrocytes from upper panel. Although in Figure 2 BRAFwt 
coronal slice is shown without a significant GFAP immunoreactivity, in some cortical slices 
of some animals there were patches of highly immunoreactive to ALDH1L1 and GFAP 
astrocytes. D. Scatter plot for BRAFV600E to control-FP showing fold change and p-values, 
data with p<0.01 is in red and was used for further functional enrichment analysis. Some of 
the genes with the highest fold change are shown. E. Scatter plot for BRAFV600E to 
BRAFwt showing fold change and p-values, data with p<0.01 is in red and was used for 
further functional enrichment analysis. . Some of the genes with the highest fold change are 
shown. F. Venn diagram of all the upregulated genes with at least log2 fold change=1, and 
p<0.01 showing some genes from  D. E. F. and G. according to their expression profile. G. 
Zoomed in y-axis scatter plot of BRAFV600E to control-FP gene expression fold change 
showing increased expression of  classic complement pathway, microglial marker Iba1 (black 
due to the red background), GFAP and vimentin. H. Zoomed in y-axis scatter plot of 
BRAFV600E to BRAFwt gene expression fold change showing smaller increase in gene 
expression of complement pathway (Serping1, Serpind1), a chemokine (Cxcl16), and 
significant decrease of Dusp7 (dephosphorylation of ERK, JNK, and p38 MAPK),C3 and 
Serpina3n expression was not significant at p<0.01. I. Venn diagram of all the downregulated 
genes with at least log2 fold change=1, and p<0.01. Scale bar 50 µm in C. 




TABLE 1 - GOTERM biological protein production pathways enrichment in Glast+ BRAFV600E 
compared to control-FP and to Glast+ BRAFwt from 402 upregulated genes at p<0.01  




collagen fibril organization 11 2.770781 14.16681 0.000007152 
response to hypoxia 19 4.785894 4.970457 0.000062725 
immune system process 24 6.04534 3.147433 0.002011456 
response to mechanical stimulus 10 2.518892 7.972663 0.002226683 
positive regulation of angiogenesis 13 3.274559 5.396373 0.002342004 
wound healing 10 2.518892 5.343381 0.038195949 
inflammatory response 19 4.785894 2.774209 0.058961929 
 
Table 2 - GOTERM Biological protein production pathways enrichment in Glast+ BRAFV600E 
compared to Glast+ control-FP and to Glast+ BRAFwt from 262 downregulated genes at p<0.01. 




neuron projection development 10 3.802281 5.807425 0.023973 
cytoskeleton organization 9 3.422053 6.985663 0.027481 
protein phosphorylation 20 7.604563 2.802889 0.031236 
potassium ion transport 10 3.802281 6.356159 0.035131 
ephrin receptor signaling pathway 6 2.281369 11.2637 0.044375 












GOAL-3 BRAFV600E TRANSFECTED NEURONS ARE 
HYPEREXCITABILE IN EX-VIVO 
 In current-clamp recordings BRAFV600E neurons displayed significantly higher action 
potential (AP) firing frequencies to 1 second depolarizing current pulses (Figure 7A upper panel, 
7B, p<0.001 for 20-300 pA current steps). This significantly increased firing rate was observed 
in neurons from both the Nestin+ and Glast+ progenitor populations. Neither BRAFwt nor 
neighboring untransfected neurons in BRAFV600E conditions showed elevated firing 
frequencies above fluorescent protein transfected controls (control-FP). Instantaneous AP 
frequency (ISF) measured at +300 pA 1 second current step was significantly higher in 
BRAFV600E neurons (Figure 7C). In addition, in 4 out of 59 Glast+ BRAFV600E neurons and 
1 out of 9 Nestin+ BRAFV600E neurons I observed an unusual bursting pattern and post-action 
potential depolarization waves that were not observed in any of the non-BRAFV600E conditions 
(Figure 7G left panel). The number of neurons with those events was increased when I recorded 
potassium currents with Co2+ (1 mM) substituting Ca2+ (1 mM) in aCSF solution (5 out of 24). In 
addition to the AP firing at a significantly higher frequency BRAFV600E neurons also had lower 
rheobase (n=49), minimal depolarizing current step required to elicit a first AP, and a lower 
voltage threshold to fire action potentials (Figure 8B, C, E). Passive membrane properties were 
also significantly different in BRAFV600E neurons. The resting membrane potential (RMP) was 
more depolarized in BRAFV600E neurons (n=61, -64.91 ± 0.76 mV) compared to untransfected 
neighbor neurons (n=23, -73.33 ± 1.55 mV, p<0.001), and input resistances measured to 
hyperpolarizing and depolarizing current pulses were significantly increased in BRAFV600E 
neurons (n=61) compared to all other non-BRAFV600E conditions (Figure 8F, G, H).  The 
elevated resting membrane potential did not explain the increased firing rates in BRAFV600E 




neurons, as untransfected neighboring neurons (n=5) did not achieve similar AP firing 
frequencies to BRAFV600E neurons when depolarized to -60 mV. The depolarized RMP in 
BRAFV600E neurons also did not correlate with more hyperpolarized AP voltage threshold 
(Figure 7 - BRAFV600E neurons are hyperexcitableD, Figure S2 Action Potential voltage threshold correlation 
to RMP). Additionally, the few BRAFV600E neurons with more negative resting membrane 
potentials (n=14, average RMP=-70.66 ± 0.58 mV) generated high frequency trains of action 
potentials like more depolarized BRAFV600E neurons (data not shown as a separate figure).  
Also, subthreshold input resistances did not correlate significantly with action potential 
frequencies in either BRAFV600E or control neurons (data not shown). Taken together, 
BRAFV600E transgenes significantly alter the electrophysiological properties of pyramidal 















Figure 7 - BRAFV600E neurons are hyperexcitable 
 
 






Figure 7. BRAFV600E expressing neurons are hyperexcitable. A. Represantative traces of four Glast+ 
experimental conditions (upper panel). Response to -40 pA 1 sec current step showing SAG ratio and rebound 
excitation measurement (lower panel). B. Input-Output curve shows more than 2 times higher AP frequency 
firing in Glast+ BRAFV600E transfected neurons (n=54 T= range of 4.37-6.73, p<0.001) and Nestin+ 
BRAFV600E transfected neurons (n=8 T= range of 5.53-9.64, p<0.001) compared to all other conditions, Glast+ 
untransfected neighbor (n=8), Glast+ control-FP (n=11), Glast+ BRAFwt (n=13), Nestin+ control-FP (n=3, 240-
300 pA), and Nestin+ untransfected neighbor (n=5, 130-300 pA). For statistical comparison for 10 pA - 150 pA 
steps, due to significant difference in variances (Levene’s test (18, 149) = range of 8.816-1.68, p<0.001, p=0.013 
for 140 pA and p=0.05 for 150 pA) Welch test with Games-Howell post-hoc correction was used; for 160-300 
pA one-way ANOVA F(18, 150) = 13.42-16.55 with Tukey post-hoc correction was used. Only cells with 7 and 
more APs at 300 pA 1 sec current step are chosen for the comparison. C. Instantaneous frequency (ISF) of APs 
in the train at 300 pA 1 second depolarizing current step was significantly higher in Glast+ BRAFV600E 
transfected neurons compared to all other conditions (p<0.001). AP ISF at +300 pA 1 second step due to 
nonhomogeneous variance for AP #1 and AP #2, Levene test (8, 132)=5.08 and 3.97 respectively, Welch test (8, 
22.91 and 23.18)=27.79 and 15.82 respectively with Games-Howell posthoc correction was used, from AP #3 
to AP #20 One-way ANOVA  F(7-8 , 82-132 )=2.24-19.6, p<0.001, with Tukey posthoc correction was used; 
there was significant difference in ISF between Glast+ BRAFV600E neurons (n=54) to Nestin+ untransfected 
neighbor (n=5, p<0.001) and Nestin+ control-FP (p<0.001); Nestin+ BRAFV600E (n=8) to their untransfected 
neighbor (p<0.001) and Nestin+ control-FP (p<0.001). D.Input-Output curve for Glast+ BRAFV600E, Glast+ 
BRAFwt held at -60 mV (n=4), and Glast+ untransfected neighbor neurons (n=5) held at -60 mV shows still 
significant difference in AP firing frequency. Due to non-homogenous variance for 30 and 40 pA steps Levene 
(2, 53)=5.5 and 4.41, p=0.007 and p=0.017 Welch test with Games-Howell post-hoc correction was used; for 
steps 50-300 pA One-way ANOVA with Tukey post-hoc correction was used. For 30-40 pA steps Welch 
F(2,10.85) = 10.43, p=0.003 and (2, 10.22)=9.78, p=0.004 respectively. For 70-300 pA steps ANOVA F(2, 
54)=3.82 – 13.84, p=0.028 and p=0.017 for 70 and 80 pA steps, p=0.007-0.001 for 90-120 pA steps; p<0.001 
for 130-300 pA steps. E. One-way ANOVA with Tukey post-hoc correction of SAG ratio values in different 
conditions shows larger SAG in most of the recorded Glast+ BRAFV600E (n=58) transfected neurons, F(3,105) 
= 35.98 (Glast+ BRAFV600E to Glast+ control-FP (n=15) – p<0.001; untransfected neighbor neurons (n=18) – 
p<0.01 , Glast+ BRAFwt (n=17) – p<0.001). SAG ratio was significantly larger in Glast+ BRAFV600E (n=58) 
compared to Nestin+ control-FP (n=5 T=2.94, p=0.005); to Nestin+ untransfected neighbor (n=4 T=3.3, 
p=0.002); Nestin+ BRAFV600E (n=8) to Nestin+ control-FP (n=5 T=4.48, p<0.001); Nestin+ BRAFV600E to 
their untransfected neighbor (T=4.87, p<0.001); Nestin+ BRAFV600E to Glast+ BRAFwt (T=5.53 p<0.001); 
Nestin+ BRAFV600E to Glast+ untransfected neighbor (T=7.3 p<0.001); Nestin+ BRAFV600E to Glast+ 
control-FP (T=5.8 p<0.001). F. Due to non-homogenous variances (Levene’s test (3, 91) = 7.61, p<0.001) Welch 
test with Games-Howell post-hoc correction was used for statistical comparison of rebound excitation values 
and shows larger rebound excitation in Glast+ BRAFV600E (n=42) transfected neurons compared to all non-
BRAFV600E Glast+ conditions Welch (3, 42.36) = 20.83, p<0.001; Glast+ control-FP (n=14, p<0.001), and 
Glast+ untransfected neighbor neurons (n=18, p<0.001), Glast+ BRAFwt (n=17, p<0.001). Rebound excitation 
was larger in Glast+ BRAFV600E neurons (n=42) compared to Nestin+ untransfected neighbor (n=4 T=3.3, 
p=0.010); to Nestin+ control-FP (n=5 T=2.94, p=0.013); it was increased in Nestin+ BRAFV600E (n=8) 
compared to their untransfected neighbor (n=4 T=5.514, p<0.001); to Nestin+ control-FP (n=5 T=6.035, 
p<0.001).BRAFV600E neurons with rebound APs were omitted from statistical comparison. G. Left upper panel 
- representative whole-cell current-clamp recording traces of Glast+ BRAFV600E transfected neuron showing 
depolarization waves with smaller spikes riding on top of them following each full size AP (4 out of 58 neurons, 
6.9%), this bursting was not observed in control conditions or BRAFwt condition. Left lower panel – zoomed in 
depolarization waves. Right panel – representative trace of rebound AP observed in 12 out of 58 (20.7%) Glast+ 
BRAFV600E transfected neurons.  * - p<0.05, ** - p<0.01, *** - p<0.001. Error bars are ±SEM for B, C, and 
D; ±2SEM for E-F. 















Figure 8. Properites of first action potential at rheobase are altered in Glast+ and Nestin+ BRAFV600E 
ectopically expressing neurons A. Averaged first APs at the rheobase traces aligned at RMP from all conditions 
with SEM zoomed-in on the left and right panels showing larger APs in untransfected neighbor neurons,and more 
hyperpolarized AP voltage threshold in BRAFV600E neurons. B. First order derivative over time (dV/dt) of 
averaged APs (phase-space plot) from all conditions showing hyperpolarised AP voltage threshold in BRAFV600E 
transfected neurons and increased AP peak in untransfected neighbor neurons. C. One-way ANOVA F(6, 
116)=9.72, p<0.001 with Tukey post-hoc correction showed that AP voltage threshold at 50 V/s  was more 
hyperpolarized in Glast+ BRAFV600E transfected neurons (n=54) compared to Glast+ control-FP (n=18, p<0.001), 
and untransfected neighbor (n=16, p<0.001); Glast+ BRAFwt (n=17, p=0.007) neurons; Nestin+ control-FP (n=5, 
p<0.001); it was lower but not statistically significant compared to Nestin+ BRAFV600E untransfected neighbor 
(n=4 T=1.81, p=0.076). AP voltage threshold at 50 V/s was significantly more hyperpolarized in Nestin+ 
BRAFV600E neurons (n=9) compared to Nestin+ control-FP neurons (n=5 p<0.001); to Nestin+ BRAFV600E 
untransfected neighbor (n=4 T=2.63, p=0.023); to Glast+ untransfected neighbor (p=0.001); to Glast+ control-FP 
(p<0.001); to Glast+ BRAFwt (p=0.012). D. One-way ANOVA F(6, 122) =6.29, p < 0.001 with Tukey post-hoc 
correction showed that AP peak measured from RMP was larger in Glast+ untransfected neighbor neurons (n=16) 
compared to Glast+ BRAFV600E (n=58, p=0.001) and to Glast+ BRAFwt transfected neurons (n=18, p=0.04); to 
Nestin+ BRAFV600E (n=9, p<0.001). Glast+ control-FP (n=18) to Nestin+ BRAFV600E (p=0.039). Nestin+ 
BRAFV600E to Nestin+ untransfected neighbor (n=4, p=0.033); to Nestin+ control-FP (n=5, p=0.002) . E. Due to 
non-homogenous variance – Levene test (6, 114) =5.55, p<0.001 Welch test with Games-Howell post-hoc 
correction was used to compare rheobase between experimental conditions, which showed lower current required 
to fire AP in Glast+ BRAFV600E transfected neurons (n=49) Welch test (6, 20.94) =36.71, p<0.001, compared to 
control-FP (n=19, p<0.001), and untransfected neighbor neurons (n=17, p<0.001), to Glast+ BRAFwt (n=18, 
p<0.001). Rheobase was significantly lower in Glast+ BRAFV600E (n=49)  compared to Nestin+ control-FP (n=5 
p<0.001); to Nestin+ untransfected neighbor (n=4 T=6.46, p<0.001); Nestin+ BRAFV600E neurons (n=9) to 
Nestin+ control-FP (n=5 T=11.52, p<0.001); to their untransfected neighbor (n=4 T=6.66, p<0.001); to Glast+ 
untransfected neighbor (p<0.001); to Glast+ control-FP (p<0.001); to Glast+ BRAFwt (p=0.004). F. Glast+ 
BRAFV600E transfected neurons (n=61) had more depolarized resting membrane potential compared to Glast+ 
control-FP neurons (n=20, p<0.001), and to their untransfected neighbor neurons (n=23, p<0.001); to Nestin+ 
untransfected neighbor (n=5, p=0.001); to Nestin+ control-FP (n=5, p=0.031). Glast+ BRAFwt transfected neurons 
(n=18) had more depolarized RMP compared to untransfected neighbor neurons (p=0.044); to Glast+ control-FP 
(p=0.050); to Nestin+ untransfected neighbor (p=0.034); to Nestin+ control-FP (T=2.25 p=0.036). Nestin+ 
BRAFV600E to Glast+ control-FP (p=0.033), and to their untransfected neighbor (p=0.005). One-way ANOVA 
F(6, 133) = 9.59, p<0.001 with Tukey post-hoc correction test was used for statistical comparison. In case of small 
n student t-test was used. RMP measured in current clamp before beginning of steps protocol. G. Due to 
nonhomogeneous variance (Levene test (6, 112) =5.58, p<0.001) Welch test (6, 24.56) =7.04, p<0.001 with Games-
Howell post-hoc correction was used for input resistance comparison. Averaged input resistance (Rin) as a function 
of membrane potential response (Vm) to depolarizing current (I) steps was significantly larger in Glast+ 
BRAFV600E transfected neurons (n=39) compared to Glast+ control-FP (n=21, p<0.001), and their untransfected 
neighbor neurons (n=23, p=0.009); to Glast+ BRAFwt (n=18, p=0.001). Glast+ BRAFV600E to Nestin+ 
untransfected neighbor (n=5, p=0.018); to Nestin+ control-FP (n=5, p=0.003). Average Rin from depolarizing 
current steps was significantly larger in Nestin+ BRAFV600E (n=8) compared to Glast+ control-FP (n=21 
T=2.496, p=0.040); to Nestin+ untransfected neighbor (n=5 T=2.418, p=0.043); to Nestin+ control-FP (n=5 
T=2.512, p=0.038).  H. Linear fit of averaged membrane potential responses to current step protocol from -40 to 
+50 pA 1 second pulse with 10 pA increment shows a different input resistance in between the recorded conditions. 
I. AP 10 V/s voltage threshold for all BRAFV600E neurons compared to control conditions at -60 mV. J. AP 50 
V/s threshold for all BRAFV600E neurons compared to control conditions at -60 mV. K. Scatter plot for AP 50 
V/s voltage threshold correlation to RMP for all BRAFV600E neurons and control conditions. * - p<0.05, ** - 
p<0.01, *** - p<0.001. Error bars are ±SEM for A. and H, ±2SEM for C-G. 
 






BRAFV600E DECREASES DELAYED RECTIFIER POTASSIUM CURRENTS  
 The exclusively increased excitability in BRAFV600E expressing neurons may be a result of 
altered ionic conductances. To test this hypothesis, I have performed whole-cell voltage clamp in 
Glast+ BRAFV600E neurons and their untransfected neighbors only. Recording of potassium 
currents showed decreased sustained currents measured at the last 100 ms of 500 ms depolarizing 
voltage pulses across examined range of voltage steps in Glast+ BRAFV600E neurons (n=18) 
compared to their untransfected neighbors (n=8, p<0.01; Table 3). The kinetic properties of 
activation were not significantly altered (Figure 9A, B, C, D, F). However, when the maximal 
sustained currents were normalized to cell capacitance, the current densities were similar between 
two conditions (Figure 9G; Table 3). Additionally, potassium currents sensitive to 25 mM TEA, a 
known potassium channel inhibitor, were also decreased in BRAFV600E neurons compared to 
their untransfected neighbors (p<0.05) without significant effect on current density (Figure 9A, B, 
C, F, G; Table 4).  The currents were recorded in the presence of 3 mM 4AP, a known inhibitor of 
fast activating potassium currents. To test the hypothesis of whether early activation of potassium 
conductances, that contributes to sustained currents can restore AP firing to control conditions in 
BRAFV600E neurons I recorded 6 neurons in whole-cell current clamp and applied 10 µM 
retigabine. Retigabine is an anti-convulsant medication that shifts voltage-dependent activation of 
M-potassium currents (carried through Kv7.2-Kv7.3 channels) to more hyperpolarized potentials 
thus causing earlier opening of the channels (Stas et al., 2016). This manipulation decreased the 
AP firing frequency of BRAFV600E neurons (Figure 9E, H), however it was still higher than in 
control conditions.  




Figure 9 - BRAFV600E decrease sustained potassium currents  
 





Table 3 - Sustained K+ current averages of maximal values and their current density 
Condition IK-Sustained maximal (pA) 
last 100 ms of 500 ms      
+20 mV pulse  
IK-Sustained maximal 
density (pA/pF) 
Cm (pF) n 
Glast+ untransfected neighbor 4062.66 ± 210.81 34.94 ± 11.76 178.04 ± 31.74 8 
Glast+ BRAFV600E 3034.19 ± 282.49** 21.30 ± 2.53 157.76 ± 13.29 18 
**  - T(23.5)=2.92, P=0.008 
 
Figure 9. Sustained potassium currents are decreased in Glast+ BRAFV600E neurons compared 
to their untransfected neighbors. A. Representative traces of potassium currents in Glast+ BRAFV600E 
neuron recorded in the presence of 3 mM 4AP, 1µM TTX, 10µM NBQX, 50µM D-AP5, 10µM SR, 50µM 
ZD7288 (5 min in, holding voltage is -80 mV, holding current -32.41 pA) with whole-cell capacitance 
compensated , grey bar indicate the region where the measurement was made in all conditions (upper 
panel); middle panel is showing the traces of the same neuron 9 min after application of 25 mM TEA 
with previous inhibitors cocktail (holding current -40.25 pA); lower panel is showing subtracted traces 
before and after 25 mM TEA with voltage step protocol. B. Representative traces of potassium currents 
in Glast+ untransfected neighbor recorded in the presence of the same inhibitors cocktail as for A (6 
min in, holding voltage is -80 mV, holding current is -48.04 pA, upper panel) with whole-cell capacitance 
compensated; middle panel is showing traces from the same neuron 9 min after application of 25 mM 
TEA with previous inhibitors cocktail (holding current -71.67 pA); lower panel is showing subtracted 
traced before and after 25 mM TEA. C. Average sustained current activation curve showing decreased 
peaks at all tested voltages in Glast+ BRAFV600E neurons compared to their untransfected neighbor 
before and after application of 25 mM TEA. D. Normalized to the maximum current and averaged 
sustained current activation curve have similar kinetics between two conditions before and after 
application of 25 mM TEA. E. Average input-output curve of 6 Glast+ BRAFV600E neurons before and 
5-17 min after beginning of 10 µM retigabine perfusion. F. Maximal sustained current measured at +20 
mV voltage step showing lower values in Glast+ BRAFV600E neurons (n=18) compared to their 
untransfected neighbors (n=8, T=2.92, p=0.008), as well as after application of 25 mM TEA (T=2.411, 
p=0.028). It was also decreased in the same neurons when comparing before and after 25 mM TEA – 
Glast+ BRAFV600E (paired sample T=2.474, p=0.035); and their untransfected neighbor (paired 
sample T=3.827, p=0.006); and comparing untransfected neighbor neurons to Glast+ BRAFV600E after 
application of 25 mM TEA (T=6.919, p<0.001). G. Current density was not different in any comparison. 
H. Representative current-clamp traces from Glast+ BRAFV600E neuron before and 15 min after 
beginning of 10 µM retigabine perfusion (upper panel). Current-clamp steps protocol (lower left panel). 
The traces from the same cell at +290 pA step overlaid with traces 15 min after retigabine perfusion.  I. 
Capacitance was measured from -5 mV steps at the beginning of each trace recording using built-in 
procedure in Axograph acquisition software before application of whole-cell capacitance compensation. 
There was no statistically significant difference in capacitance measurements between the experimental 
conditions. J. Input resistance was significantly increased in Glast+ BRAFV600E (n=18) compared to 
their untransfected neighbors (n=8, T=3.293, p=0.003), it was increased in Glast+ BRAFV600E neurons 
(n=7) compared to their untransfected neighbors (n=4), but not statistically significant (T=2.223, 
p=0.053); it was significantly increased in Glast+ BRAFV600E neurons (n=7) after application of 25 mM 
TEA compared to their untransfected neighbors before application of TEA (n=8, T=3.664, p=0.009). * - 
p<0.05, ** - p<0.01, *** - p<0.001. Error bars are ±SEM for C. and D, ±2SEM for E-H. 
 




Table 4 – TEA sustained K+ current averages of maximal values and their current density  
Condition IK-Sustained peak (pA) last   
100 ms of 500 ms                     
+20 mV pulse TEA 
sensitive 
n  IK-Sustained density TEA 
sensitive (pA/pF) 




2484.56 ± 258.29  8  12.23 ± 3.85 239.88 ± 59.23 4 
Glast+ 
BRAFV600E 
1561.06 ± 266.57* 11  7.28 ± 1.36 187.18 ± 18.45 7 
*  - T(17)=2.41, P=0.028 
 
BRAFV600E INCREASE IH CURRENT 
In response to hyperpolarizing current pulses in whole-cell current clamp mode BRAFV600E 
neurons in either Glast+ or Nestin+ condition displayed an initial deflection, SAG ratio that was 
absent in untransfected neighbor neurons, control-FP neurons, and in BRAFwt neurons (Figure 
10A lower panel, 10E). SAG ratio was calculated as  𝑆𝐴𝐺 = (1 −
𝑉𝑅𝑀𝑃− 𝑉𝑠𝑠
𝑉𝑅𝑀𝑃− 𝑉𝑚𝑖𝑛
) ∗ 100%, VRMP – 
Resting Membrane Potential, Vss – stable-state voltage in the last 100 ms of 1 second -40 pA pulse, 
Vmin – minimal initial voltage deflection in response to 1 second -40 pA pulse.  Glast+ 
BRAFV600E neurons (n=57) had average SAG ratio of 23.41 ± 1.33% that was significantly larger 
than in their untransfected neighbor neurons of 4.46 ± 1.48% (n=20, p=0.001); and in Glast+ 
control-FP neurons 6.82 ± 1.86% (n=15, p<0.001); and in Glast+ BRAFwt neurons 6.59 ± 1.94% 
(n=17, p<0.001) (Figure 7E). In Nestin+ BRAFV600E average SAG was 24.48 ± 2.27 % (n=8) 
and it was significantly increased compared to all non-BRAFV600E conditions (p<0.001, Figure 
7F). In Nestin+ control-FP the average SAG ratio was 10.03 ± 1.77% (n=5); and in Nestin+ 
untransfected neighbor the average SAG ratio was 6.59 ± 2.41% (n=4).  
Average rebound excitation measured as an overshoot above RMP at the end of 1 second 
-40 pA current step was also larger in Glast+ BRAFV600E neurons (n=42) 2.28 ± 0.24 mV 




compared to their untransfected neighbor neurons 0.69 ± 0.18 mV (n=22, p<0.01); to Glast+ 
control-FP neurons 0.37 ± 0.11 mV (n=14, p<0.01); to Glast+ BRAFwt neurons 0.34 ± 0.06 mV 
(n=17, p<0.01); to Nestin+ untransfected neighbor 0.18 ± 0.27 mV (n=4, p<0.05); to Nestin+ 
control-FP 0.47 ± 0.13 mV (n=5, p<0.05). In Nestin+ BRAFV600E rebound excitation was 
increased, (n=7) 1.82 ± 0.17 mV compared to non-BRAFV600E conditions (to Glast+ BRAFwt - 
p<0.001; to Glast+ untransfected neighbor – p=0.02; to Glast+ control-FP – p<0.001; to Nestin+ 
untransfected neighbor – p<0.001; to Nestin+ control-FP – p<0.001)  (Figure 7H). In 20.34% of 
Glast+ BRAFV600E neurons (12/59) and in 11.11% of Nestin+ BRAFV600E (1/9) rebound 
excitation resulted in AP firing (Figure 7G upper right panel).   
 Increased SAG ratio and rebound excitation has been previously shown in layer 5 cortical, 
hippocampal and non-cortical neurons in mice, rats and cats to be associated with 
hyperpolarization activated conductances (Guan et al., 2015; Hawkins et al., 2015; Jung et al., 
2010; Schridde et al., 2006; Timofeev et al., 2002). To test whether BRAFV600E ectopically 
expressing neurons have increased hyperpolarization activated conductance I recorded cells in 
whole-cell voltage clamp configuration. The BRAFV600E expressing neurons had increased Ih 
compared to all other conditions and have half activation voltage of V1/2 = -82.79 mV and the slope 
factor k = 11.58-1 mV using recording protocol that holds the cell at -50 mV and the first voltage 
step is at -120 mV with 5 mV increment for 1.5 seconds (Figure 10; Table 5). This current was 
blocked with application of 50 µM ZD7288, a known Ih inhibitor in perfusion system and recorded 
at least 5 minutes later. Ih peak was only significantly increased in Glast+ BRAFV600E neurons 
(n=17) compared to their untransfected neighbors (n=6, p<0.05), however when normalized to cell 
capacitance the Ih peak current density was significantly increased in Glast+ BRAFV600E neurons 
compared to their untransfected neighbors (p<0.001), and to Nestin+ control-FP (n=4, p<0.001). 




In Nestin+ BRAFV600E neurons (n=4) the Ih peak current density was significantly increased 
compared to Glast+ untransfected neighbors (p<0.05), and to Nestin+ control-FP (p<0.05). 
Consistent with that application of ZD7288 decreased SAG and rebound excitation in 
BRAFV600E neurons (Figure 11). 
  Figure 10 - IH is increased in BRAFV600E neurons 
  
 





Table 5 -  Ih peak and current density. 
 * - Ih was recorded with the first voltage step starting at -100 mV 
 
Condition Ih peak -50 -120 
mV (pA) 
Ih peak density        -
50 -120 mV (pA/pF) 
Cm (pF) n 
Glast+ control-FP -129.22 -1.02 126.94 1 
Glast+ untransfected neighbor -174.17 ± 58.24 -0.92 ± 0.30 193.03 ± 24.99 6 
Glast+ BRAFwt -66.22 ± 13.03* -0.36 ± 0.08 253.49 ± 41.27 12 
Glast+ BRAFV600E - 446.58± 58.24 -3.45 ± 0.37 135.95 ± 14.18 18 
Nestin+ control-FP -197.17 ± 93.19 -0.85 ± 0.28 214.29 ± 44.06 4 
Nestin+ untransfected neighbor -117.75 -1.13 104.00 1 
Nestin+ BRAFV600E -322.76 ± 54.45 -2.97 ± 0.63 84.34 ± 32.33 4 
Figure 10. Hyperpolarization activated depolarizing current (Ih) recorded in whole-cell voltage-
clamp configuration is increased in BRAFV600E ectopically expressing cortical neurons of layers 
2/3. A., B., C., D. Representative traces of currents in response to hyperpolarizing voltage step 
protocols shown in the lower panels. Note that Glast+ BRAFwt was recorded at the same holding 
potential as all other conditions with the first hyperpolarizing voltage steps been -100 mV and not -
120mV. E., F., G. Application of 50 µM ZD7288, a known Ih inhibitor, in perfusion system and 
recorded 5 minutes later blocked Ih. H. Average Ih activation curves of all conditions measured from 
the tail current as shown in C. (dashed circle). Measurement was done after off-line leak subtraction. 
Note that due to absence of tail currents in both control conditions, as well as in Glast+ BRAFwt 
condition the normalized averaged values relative to holding current of the activation are negative. 
I. Ih activation curve from the voltage steps protocol shown in A. lower panel with maximal activation 
around -120 mV half activation -82.79 mV and k slope factor of 11.58-1 mV, that are averaged and 
fit with Boltzmann curve (n=18) J. Ih peak current measured as shown in C., recorded with protocol 
shown in A lower panel Glast+ control-FP (n=5), Glast+ untransfected neighbor (n=6), Glast+ 
BRAFV600E (n=24). Color code matched between the figures shown in A. Circle blue – Glast+ 
control-FP, circle black Glast+ untransfected neighbor, diamond red – Glast+ BRAFV600E, diamond 
magenta – Glast+ BRAFwt, purple square – Nestin+ BRAFV600E, orange square – Nestin+ 
untransfected neighbor, brown square – Nestin+ control-FP. Ih peak currents (left panel) quantified 
for all conditions, the significant increase was only found in Glast+ BRAFV600E neurons (n=17) 
compared to their untransfected neighbors (n=6, T=2.117, p=0.046); middle panel - cell capacitance 
measured from -5mV voltage steps at the beginning of each trace recording using built-in Axograph 
acquisition software procedure without any whole-cell and series resistance compensation; the 
capacitance was decreased in Glast+ BRAFV600E neurons (n=16) compared to Nestin+ control-FP 
(n=4, T=2.223, p=0.039), and in Nestin+ BRAFV600E neurons (n=4) compared to Glast+ 
untransfected neighbors (n=6, T=2.338, p=0.048); right panel – Ih peak density was increased in 
Glast+ BRAFV600E neurons (n=16) compared to their untransfected neighbor (n=6, T=3.918, 
p<0.001), to Nestin+ control-FP (n=4, T=5.546, p<0.001); it was also significantly increased in 
Nestin+ BRAFV600E neurons (n=4) compared to Glast+ untransfected neighbors (n=6, T=3.275, 
p=0.011), and to Nestin+ control-FP (n=4, T=3.066, p=0.022). Error bars are ±SEM and for H and I; 
±2SEM for J. 










Figure 11. Effect of 50 µM ZD7288 on SAG and rebound excitation. A. Current-clamp traces of BRAFV600E 
neuron in response to 1s current pulses shown in the lower panel. B. The same neuron 3 min after application of 
50 µM ZD7288 in perfusion showing more hyperpolarized membrane potential. C. overlay of A. and B. C. D. 
Effect of 50 µM ZD7288 on SAG in 3 BRAFV600E neurons. E. Effect of 50 µM ZD7288 on rebound excitation 
in 3 BRAFV600E neurons. 
 




BRAFV600E INCREASES FREQUENCY OF EXCITATORY POST-SYNAPTIC EVENTS 
  Next, we tested how BRAFV600E alters synaptic activity in transfected 
cortex. I recorded spontaneous Post-Synaptic Currents (sPSCs) in whole-cell voltage clamp 
configuration in all conditions holding the cells at -70 mV and compared the instantaneous 
frequency and amplitude distributions with nonparametric Mann-Whitney U test (Figure 12C, D). 
I found that Glast+ BRAFV600E neurons had significantly higher sPSCs instantaneous frequency 
(ISF) (n=25, average of 20.36 ± 0.17 Hz) compared to Glast+ control-FP neurons (n=5 average of 
15.93 ± 0.39 Hz, p<0.001), and to Glast+ BRAFwt neurons (n=9 average of 17.25 ± 0.28 Hz, 
p<0.001). Interestingly Glast+ BRAFV600E neurons had lower ISF compared to untransfected 
neighbor neurons (n=7 average of 24.29 ± 0.25 Hz, p=0.04). Untransfected neighbor neurons had 
higher ISF compared to Glast+ BRAFwt (p<0.001), and to Glast+ control-FP (p<0.001). Glast+ 
BRAFwt neurons had higher ISF compared to Glast+ control-FP (p=0.04). Nonparametric Mann-
Whitney U test showed that amplitudes were only different in Glast+ control-FP compared to all 
Glast+ conditions (Figure 12E, F; p< 0.001). In all Nestin+ conditions the cumulative distribution 
of inter-events intervals (IEI) showed a significant left shift indicating a higher ISF compared to 
Glast+ conditions (p<0.001) except for Glast+ untransfected neighbor neurons that had higher ISF 
(p<0.001).  I have also recorded miniature post-synaptic currents (mPSCs) in a few BRAFV600E 
expressing neurons that showed that the ISF of mPSCs was not significantly different from ISF of 













Figure 12 - sPSCs frequencies are increased in BRAFV600E neurons, and in their 
untransfected neighbors 
 










Figure 12. BRAFV600E expression under both Glast+ and Nestin+ alters spontaneous Post-Synaptic Currents 
frequencies. A. Representative traces. B. zoom in. C. Cumulative distribution of Inter-event intervals (IEI) 
compared with nonparametric Mann-Whitney U test showing that Glast+ BRAFV600E (red, n=25) had 
significantly lower ISF compared to their untransfected neighbor neurons (black left shifted curve, n=8 
U=56162614, p<0.001); higher ISF compared to Glast+ control-FP (blue right shifted curve, n=6 U=14230311, 
p<0.001); higher ISF compared to Glast+ BRAFwt (magenta right shifted curve, n=10 U=34173926, p<0.001); 
lower ISF in Glast+ BRAFwt neurons compared to Glast+ untransfected neighbor (U=15082733, p<0.001); 
higher ISF in Glast+ BRAFwt compared to Glast+ control-FP (U=5015372.5, p=0.04); and higher ISF in Glast+ 
untransfected neighbor neurons to Glast+ control-FP (U=6221684.5, p<0.001). sPSCs frequencies are not 
significantly different in Nestin+ BRAFV600E (purple, n=8) compared to Nestin+ untransfected neighbor 
neurons (bright orange, n=5 U=3972278.5, p=0.25); compared to Nestin+ control-FP (brown, n=3 U= 3540666.5, 
p=0.96). sPSCs instantaneous frequencies were significantly increased in Nestin+ BRAFV600E neurons (n=8) 
compared to Glast+ BRAFV600E neurons (red, n=25 U= 35788328, p<0.001); to Glast+ untransfected neighbors 
(black, n=7 U= 19800832, p<0.001); to Glast+ control-FP (blue, n=5 U= 3943628.5, p<0.001); Nestin+ 
untransfected neighbor neurons (bright orange, n=5) to Glast+ BRAFV600E neurons (red n=25 U= 11670220.5, 
p<0.001); to Glast+ untransfected neighbor neurons (black, n=8 U= 6220354, p<0.001); to Glast+ control-FP 
(blue, n=5 U= 1299202.5, p<0.001); Nestin+ control-FP (brown, n=3) to Glast+ BRAFV600E neurons (red, n=25 
U= 10059716, p<0.001); to Glast+ untransfected neighbor neurons (black, n=8 U= 5534089, p=0.016); to Glast+ 
control-FP (blue, n=5 U= 1119629.5, p<0.001). D. Averaged sPSCs ISF per neurons. Comparison is as in C. E. 
Cumulative distribution of sPSCs amplitudes  showing that amplitudes from Glast+ BRAFV600E neurons are 
not significantly different from their untransfected neighbor neurons (U=64347671, p=0.33); and Glast+ BRAFwt 
(U=38622212, p=0.82); but it was significantly increased compared to Glast+ control-FP (U=15598177.5, 
p<0.001); sPSCs amplitudes was not significantly different between Glast+ untransfected neighbor neurons and 
Glast+ BRAFwt (U=19867509, p=0.39); it was significantly increased in Glast+ untransfected neighbor neurons 
compared to Glast+ control-FP (U=8174115, p<0.001); and in Glast+ BRAFwt compared to Glast+ control-
FP(U=4806537, p<0.001). Lower amplitudes in Nestin+ BRAFV600E (purple, n=8) and their untransfected 
neighbor neurons (bright orange, n=5) compared to Nestin+ control-FP neurons (brown, n=3 U= 3019414.5, 
p<0.001; and U= 935101, p<0.001 respectively). Significantly larger sPSCs amplitudes in Nestin+ BRAFV600E 
neurons (n=8) compared to Glast+ BRAFV600E neurons (red, n=25 U= 36907544, p<0.001); to Glast+ 
untransfected neighbors (black, n=8 U= 18847821.5, p<0.001); to Glast+ control-FP (blue, n=5 U= 4639404, 
p<0.001); Nestin+ untransfected neighbor neurons (bright orange, n=5) to Glast+ BRAFV600E neurons (red 
n=25 U= 11751080.5, p<0.001); to Glast+ untransfected neighbor neurons (black, n=8 U= 6015340.5, p<0.001); 
to Glast+ control-FP (blue, n=5 U= 1481496.5, p<0.001); Nestin+ control-FP (brown, n=3) to Glast+ 
BRAFV600E neurons (red, n=25 U= 8523478, p<0.001); to Glast+ untransfected neighbor neurons (black, n=8 
U= 4268880.5, p<0.001); to Glast+ control-FP (blue, n=5 U= 1113151, p<0.001). F. Averaged sPSCs amplitudes 
per neurons. Comparison as in E. * - p<0.05, ** - p<0.01, *** - p<0.001. 
 




UNSUPERVISED HIERARCHICAL CLUSTER ANALYSIS INDICATES BRAFV600E 
TRANSFORMATION OF PYRAMIDAL NEURON CELL TYPE PHYSIOLOGY. 
 I used Hierarchical Cluster Analysis together with Principal Component Analysis to test 
whether the BRAFV600E ectopically expressing neurons segregate according to the 
electrophysiological parameters recorded in whole-cell patch-clamp experiments. After centering 
to the mean and dividing by standard deviation I used Gene Cluster 3.0 software with correlation 
(uncentered) setting HCA. Using Gene Pattern web software tool from broad institute of MIT, 
HCA showed that BRAFV600E transfected neurons segregate to the cluster according to their 20 
electrophysiological properties recorded (Figure 13). Using Principal Component Analysis with 
XLSTAT Excel addon I found that the first two principal components explain 48.88% variability 
across electrophysiological parameters in 4 conditions. Major contributing parameters to the 
variability where AP Frequency at 300 pA 1s pulse, Rheobase, AHP, AP voltage threshold and 
maximal rising AP voltage slope. Some of them presented in 3D scatter plots in Figure 13. 











Figure 13 - Unsupervised hierarchical clustering of the electrophysiological properties 
showed segregation of BRAFV600E neurons from other conditions  
 
Figure 13. Glast+ and Nestin+ BRAF V600E ectopically expressing neurons segregate to separate 
clusters in HCA analysis of electrophysiological properties. A. Unsupervised Hierarchical Cluster 
Analysis was performed on 20 recorded electrophysiological parameters and showing that most of the 
BRAFV600E neurons segregate together by electrophysiological parameters recorded. The parameters 
are AP width at 50% height from RMP in ms, AP maximal decay slope in V/s, AP decay time from 100% 
to 50% height in ms, AP rise time from 10% to 90% height in ms, AP 50 V/s voltage threshold in mV, 
AP 10 V/s voltage threshold in mV, rheobase in pA, AHP measured at the end of +300 pA 1 second 
current step in mV, AP peak relative to RMP in mV, AP maximal rise slope in V/s, RMP in mV, Rin from 
hyperpolarizing pulses in MΩ, Rin from depolarizing pulses in MΩ, average sPSCs amplitude in pA, 
average sPSCs instantaneous frequency in Hz, mAHP measured relative to 10 V/s AP voltage threshold 
for rheobase APs in mV, SAG ratio in %, AP frequency at +300 pA 1 second current step in Hz, number 
of APs at rheobase,  rebound excitation measured as an overshoot above RMP (mV).  B. Most 
contributing electrophysiological parameters to the variability in PCA shown in 3D plots – upper left 
panel SAG ratio on the Z axis, AP number at +300 pA 1 second pulse is on the X axis and rebound 
excitation is on the Y axis. C. SAG ratio on the Z axis, AHP at the end of +300 pA 1 second pulse on 
the X axis and rebound excitation on the Y axis. D. Rheobase on the Z axis, AP maximal rise slope is 
on the X axis, and AP 50V/s voltage threshold on the Y axis. E. AP number at +300 pA 1 second pulse 
on the Z axis, resting membrane potential (RMP) is on the X axis, Input resistance from depolarizing 
current pulses (Rin) is on the Y axis.  




OTHER SOMATIC MUTATIONS ASSOCIATED WITH FOCAL CORTICAL 
DYSPLASIAS CAUSE CHANGES IN ELECTROPHYSIOLOGICAL PROPERTIES 
DISTINCTLY DIFFERENT FROM BRAFV600E 
 
To compare BRAFV600E electrophysiological properties to previously published MTOR 
related mouse models of brain overgrowth - a mutation in Phosphatidylinositol-4,5-Bisphosphate 
3-Kinase Catalytic Subunit Alpha (PIK3CA E545K) (Roy et al., 2015), and CRISPR-Cas9 induced 
insertion-deletion in Tuberous Sclerosis 1/2 (TSC1/TSC2) genes (Lim et al., 2017) I directed 
PIK3CAE545K transgene into Glast+ neuronal progenitors, and used CRISPR guide-RNA T4 for 
TSC1 and T7 for TSC2 from Lim et al., 2017 to transfect neuronal progenitors at E14-E15. The 
AP firing frequency, AP ISF, rheobase, RMP and Rin was closer to control conditions in previous 
experiments (Figure 14A upper panel, 14B, 14C, 14D, 14F, 14G). However, AP voltage threshold 
was not different from Glast+ BRAFV600E neurons.  The T7 TSC2 experiments did not show 
significant differences compared to their untransfected neighbors and to CRISPR-Cas9 without 
any guide-RNA controls, probably reflecting a minor difference in TSC2 sequences between 
mouse lines used in our experiments and in Lim et al., (2017).  Comparison of action potential 
dependent mixed glutamatergic and GABAergic synaptic events showed that frequencies of those 
events were significantly higher in Glast+ PIK3CAE545K and TSC1 CRISPR-Cas-9 KD 
compared to Glast+ BRAFV600E but not to BRAFV600E untransfected neighbor neurons (Figure 
15). This suggest that alterations in neuronal electrophysiological properties affected differently 
by pathological mutations in MTOR pathway key protein components.   
 
 




Figure 14 - Different somatic mutations in MTOR and MAPK pathways have different 


















Figure 14. Differential effect of three experimental manipulations on whole-cell current-clamp properties. A. 
Representative traces from Glast+ neurons ectopically expressing PIK3CA E545K (blue) and BRAFV600E 
mutations (red), and CRISPR knockdown of TSC1 gene showing AP firing at +300 pA (upper panel), and 
membrane potential response to hyperpolarizing current step of -40 pA.  B. Average AP firing frequency in all 
three conditions, BRAFV600E (n=54), TSC1 KD (n=11), PIK3CA E545K (n=6). Cells with maximal values are 
shown for PIK3CA E545K (half-filled blue circles), and for TSC1 KD (brown spheres). C. AP instantaneous 
frequency at +300 pA current step except TSC1 KD, which is shown for +450 pA current step with maximal value 
cell shown for +300 pA current step (brown spheres). D. Rheobase for all three conditions was compared with 
Welch test (2, 14.38) =72.98 due to nonhomogeneous variance (Levene test (2, 68) =15.36, p<0.001), together 
with Games-Howell posthoc correction BRAFV600E to TSC1 KD (p<0.001), BRAFV600E to PIK3CA E545K 
(p=0.011, due to small sample for PIK3CA E545 student T=3.68, p=0.004 was used), . E. AP 50 V/s voltage 
threshold is not different compared with Welch (2, 19.59) =2.48, p=0.11) together with Games-Howell 
BRAFV600E to TSC1 KD (p=0.57), BRAFV600E to PIK3CA E545K (p=0.12); Levene test (2, 73) =4.93, 
p=0.01. F. Resting Membrane Potential (RMP recorded before application of current steps) was compared with 
One-way ANOVA F(2,86) =28.72, together with Tukey posthoc corrections BRAFV600E to TSC1 KD (p<0.001), 
and BRAFV600E to PIK3CA E545K (p<0.001). G. Input resistance (Rin) from depolarizing current steps (due to 
Ih activation in BRAFV600E) was compared with Welch (2, 25.70) =74.48, due to nonhomogeneous variance 
(Levene test (2, 61) =3.40, p=0.04), together with Games-Howell posthoc correction BRAFV600E to TSC1 KD 
(p<0.001), and BRAFV600E to PIK3CA E545K (p<0.001). * - p<0.05, ** - p<0.01, *** - p<0.001. 




Figure 15 - SPSCs frequencies are increased in Nestin+ BRAFV600E neurons compared 





Figure 15. Spontaneous Post-Synaptic Currents (sPSCs) frequencies in different experimental conditions. A. 
sPSCs recorded in Glast+ BRAFV600E neurons (n=25), in their untransfected neighbors (n=8), in Glast+ control-
FP (n=6), Glast+ BRAFwt (n=10), Glast+ PIK3CAE545K (n=8), their untransfected neighbors (n=3), CRISPR-
Cas9 TSC1 KD (n=13), their untransfected neighbors (n=5), CRISPR-Cas9 TSC2 KD (n=11), their untransfected 
neighbors (n=5). B. Averages of sPSCs frequencies per cell. C. Averages of sPSCs amplitudes per cell. The dashed 
grey line is aligned to the average of Glast+ control-FP. 




CHAPTER 4 CAVEATS AND FUTURE EXPERIMENTS 
 In current work I have tested the effect of acute BRAFV600E inhibition with specific blocker 
Vemurafenib (PLX4032, PLX4720) on excitability in BRAFV600E neurons. This FDA approved 
cancer medication was developed for unresectable or metastatic melanoma treatment (Bollag et 
al., 2010; Lee et al., 2010). Preincubation of BRAFV600E transfected cortical slices in 10-50 µM 
of Vemurafenib for 1-5h did decrease action potential firing frequency, but this effect was 
indistinguishable in slices preincubated in comparable amount of solvent (DMSO). This was also 
consistent with previous work examining the effect of DMSO on neuronal excitability in layer 2 
of perirhinal cortex (Tamagnini et al., 2014). Similar results were obtained for Rapamycin 
experiments, which was also dissolved in DMSO. Further experiments to test different RAS-RAF-
ERK pan-inhibitors that are soluble in other solvents may show the effect of acute inhibition of 
BRAFV600E on neuronal excitability. The decreased sustained potassium currents in 
BRAFV600E neurons, probably resulted from deactivation of potassium channels, since early 
activation of some of the potassium channels contributing to the sustained currents with acute (5-
17 minutes) retigabine application decreased AP firing frequency significantly more than 
Vemurafenib or DMSO. This suggest that the hyperexcitability in BRAFV600E driven LNETs 
may be ameliorated with retigabine, or retigabine-like agents with less side-effects and toxicity 
(Rubi et al., 2017; Brickel et al., 2012). 
Histopathological examination of immunopositivity to CD34, a hematopoietic stem cell 
marker previously shown to label extensively LNETs (reviewed in Thom et al., 2012), showed 
only few immunopositive neuronal cells. 




 The Nestin+ conditions presented here have small sample size, but comparison of 
hyperexcitability, dysmorphogenesis, activation of astrocytes with other conditions shows that 
these few examples did partially capture the effects observed in Glast+ BRAFV600E cells with 
distinct differences. Additionally, five brains out of six from different litters had larger cells 
located closer to the lateral ventricle, suggesting that the effect of BRAFV600E may be 
progenitors’ populations dependent. However, more experiments are needed to make a better 
estimation of such an effect.  
Stimulation of BRAFV600E transgenic neurons with ChR2 in Nestin+ condition with high 
power blue laser under high extracellular potassium concentration may differentiate BRAFV600E 
condition from control-FP based on the amount of stimulation required to initiate ictal activity 
(threshold) (Chung et al., 2018). Stimulation with the blue laser of ChR2 and BRAFV600E 
transfected cortical slices perfused with 6 mM extracellular potassium did not show ictal-like 
discharges, suggesting that reduced connectivity in slice preparation may present a challenge for 
testing epileptiform activity in slices in those experiments.  
CHAPTER 5 CONCLUSION 
 BRAFV600E somatic mutation when expressed in neuronal progenitors that produce both 
neurons and astrocytes increase excitability of layer 2/3 neurons in mouse somatosensory cortex 
as evident by increased AP firing frequency, depolarized RMP, increased Rin and hyperpolarized 
AP voltage threshold. It also increases hyperpolarization activated depolarizing conductances (Ih). 
(Figure 7, Figure 10, Figure 11) The increased AP firing frequency is not solely due to depolarized 
RMP, and depolarizing holding potential to around -60 mV for the control conditions and BRAFwt 
neurons did not increase the AP firing frequency to the same levels as in BRAFV600E expressing 




neurons (Figure 7). Increased sPSCs frequency in BRAFV600E expressing neurons, which 
accounts for 5-10% of all cortical neurons (Rice et al., 2010) occurred together with increased 
sPSCs frequency in their untransfected neighbor neurons suggesting non-cell-autonomous effect 
of BRAFV600E expression (Figure 12). Unsupervised hierarchical Cluster Analysis showed that 
using 20 electrophysiological properties of the recorded 154 neurons BRAFV600E mostly 
segregate closer together with interesting few untransfected neighbor neurons interspersed in 
between (Figure 13). Those untransfected neighbor neurons either had non-cell autonomous effect, 
or they actually were transfected with BRAFV600E but not EGFP considering that the rate of co-
transfection of multiple plasmids in IUE is around 90-95% (Figueres-Onate et al., 2015). 
Expression of BRAFV600E, which increases activation of MAPK pathway also increases 
percentage of astrocytes compared to neurons (Figure 3), these results corroborate previous work 
on MAPK pathway activation by Li et al. (2012). Li et al. (2012) showed that constitutively active 
MEK1, a downstream effector protein to BRAF when electroporated at E15.5 under ubiquitously 
active pCAG promoter increases gliogenesis of transfected neuroglial progenitor population. 
Additional support to that comes from another study by Li et al. (2014) that used ectopic expression 
of BRAFV600E in Neurog2+ and Ascl1 mouse lines. Those astrocytes are activated as evident 
through increased immunopositivity for GFAP in transfected area of cortical slices (Figure 5). 
Additionally, some of the BRAFV600E expressing neurons destined for upper cortical layers 2/3 
mislocalized to the lower cortical layers 4-6 (Figure 3, Figure 4). Cellular morphological 
alterations observed in BRAFV600E transfected mouse somatosensory cortices included balloon-
like cells that were observed at all examined post-natal ages. The aggregates of those cells were 
observed starting at P30 post-natal age. Those balloon-like cells may be immunopositive for both 
cortical layer markers – Cux1 and Ctip2, and some may not express neuronal nuclear marker 




NeuN. Inflammatory immune system is overactivated in BRAFV600E mouse cortices together 
with classic complement pathway.  The increased gene expression of innate inflammatory immune 
system, classic complement pathway and microglia markers (Iba1, CD74 – HLA-DR) are in line 
with findings of other studies in human resected GG tumors (Aronica et al., 2008b). More 
interestingly, they also in line with findings from resected human tubers from TSC patients (Boer 
et al., 2010a). Video and electrocorticographic recording showed epileptiform activity with 
behavioral manifestation suggesting that this mouse model did capture the symptomatic 
pathophysiology of LNETs. Those include cellular dysmorphogenesis, neuronal mislocalization,  
increased astrogliosis and activation of microglia, increased innate inflammatory response with 
complement pathway activation and seizure-like ictal electrographic discharges with motor 























Figure S1. Immunoreactivity to Iba1. Upper 3 panels show Immunoreactivity to Iba1 in Glast+ conditions. 
Lower panels show balloon-like cells surrounded by Iba1 positive cells. Scale bars 500 µm upper panels. 50 µm 
lower panels. 









Figure S2. AP voltage threshold is not correlated with depolarized resting membrane potential in Glast+ 
BRAFV600E neurons and other conditions held at -60 mV. A. Scatter plot of AP voltage threshold vs. RMP 
showing low correlation coefficient B. Same as A, excluding the single outlier and including other conditions. C. 
AP 10 V/s voltage threshold (closer to the kink on dV/dt plot). Two tailed T(60)=5.043, p<0.001 for BRAF V600E 
to controls combined; T(14)=2.757, p=0.015 for BRAFwt to controls combined.. D. AP 50 V/s voltage threshold. 
Two tailed T(61)=3.466, p=0.001. * - p<0.05, ** - p<0.01, ** - p<0.001 




















Figure S3. Miniature post-synaptic currents in Glast+ BRAFV600E neurons. A. Cumulative distribution of 
the inter-events interval and average instantaneous frequencies of spontaneous post-synaptic currents (sPSCs) and 
miniature post-synaptic currents (mPSCs). Miniature post-synaptic currents were recorded in the same neurons 
after at least 3 min in 3 µM TTX in the perfusion system. B. sPSCs and mPSCs amplitudes cumulative distribution 
and averages per cell.  
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